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ABSTRACT
A ROLE FOR THE HYDROXYBENZOIC ACID METABOLITES OF FLAVONOIDS
AND ASPIRIN IN THE PREVENTION OF COLORECTAL CANCER
RANJINI SANKARANARAYANAN
2021
Flavonoids are a group of polyphenolic compounds, with established antioxidant
properties, that are present ubiquitously in plants, fruits, and vegetables. Their universal
presence in nature is evident by the fact that more than 4000 types of flavonoids have been
identified till date. Additionally, they have also become part of the daily diet through
consumption of fruits such as berries, grapes, pomegranate, and cherries, and vegetables
such as onions, kale, and eggplant. High levels of flavonoids are also consumed through
beverages such as tea and red wine. Numerous studies have demonstrated that a diet rich
in flavonoids decreases the incidences of colorectal cancer (CRC). Interestingly, the cancer
prevention properties of flavonoids are also shared with a structurally unrelated compound
– aspirin. Aspirin is a drug commonly used since 1897 for its anti-inflammatory, antipyretic and pain-relieving properties; however, it is synthesized from salicylic acid, which
is commonly found in plant sources. In the last two decades, it has been recommended as
an anti-thrombotic drug to prevent heart attacks in the general population. The interest in
aspirin research piqued following the initial report in 1988, suggesting that regular
consumption of aspirin decreases CRC incidences. In view of the increased incidence of
cancer worldwide, the reports of the ability of flavonoids and aspirin to decrease cancer
was highly significant. This led to extensive research of these compound to elucidate and
understand the mechanisms of their cancer preventive actions. However, despite decades

xxii

of efforts, a consensus has not been reached on their specific modes of action. This research
investigation was thus initiated to address this lacuna and to identify novel pathways of
cancer prevention by these compounds.
An important investigative line of research is to address the question – why are both
aspirin and flavonoids preferentially protecting against CRC as opposed to cancers of the
other tissues? Reports in literature suggested that a significant amount of both these
compounds are left unabsorbed in the intestine, and therefore we considered the possibility
that both flavonoids and aspirin may directly target colorectal tissues to exert their
anticancer effects before they are absorbed into circulation. Apart from liver metabolism,
reports also exist on the biotransformation of flavonoids and aspirin in the intestinal lumen,
by the actions of the resident microflora. Hence, if one were to consider this line of
investigation, it was also important to consider the metabolites that are generated from
these compounds through microbial degradation in the intestine. Currently, there are
minimal investigations carried out to determine the role of these metabolites in the
prevention of CRC, and therefore represents an important area for further research. The
studies described in this dissertation, therefore, focuses on metabolites that are known to
be generated from flavonoids and aspirin, their cellular targets, and their ability to inhibit
CRC cell growth. We hypothesize that metabolites of flavonoids and aspirin may inhibit
cancer cell growth through the inhibition of cyclin dependent kinases (CDKs). We focused
on CDKs as the primary targets of these metabolites because cancer is marked by the
dysregulation of the cell cycle. Since the gut microbiota are the major sources of these
metabolites in the intestine, an initial investigation was also carried out to identify the
bacterial species capable of degrading the flavonoid quercetin to generate bioactive
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metabolites. Owing to experimental constraints, the identification of bacterial species
capable of biotransforming aspirin and salicylic acids have not been performed.
Flavonoids metabolism has been demonstrated to generate 3,4-dihydroxybenzoic acid
(3,4-DHBA), 3,4,5-trihydroxybenzoic acid (3,4,5-THBA), 2,4,6-trihydroxybenzoic acid
(2,4,6-THBA), 4-hydroxybenzoic acid (4-HBA), and 3,4-dihydroxyphenyl acetic acid
(DOPAC) to name a few. Among these, some studies exist on the ability of 3,4-DHBA,
3,4,5-THBA and DOPAC to prevent cancer cell proliferation. However, no studies exist
on the anti-proliferative ability of 2,4,6-THBA against cancer cells. Chapter 3 focuses on
this metabolite with regards to identification of cellular targets, as well as its effect on
cancer cell growth. Our studies have demonstrated that 2,4,6-THBA inhibited CDK
enzyme activity and cancer cell proliferation in vitro. 2,4,6-THBA dose-dependently
inhibited CDKs 1, 2 and 4, and in silico studies identified key amino acids involved in
these interactions. Interestingly, the structurally related compounds 3,4-DHBA and 3,4,5THBA did not inhibit CDK enzyme activity. We also showed that cellular uptake of 2,4,6THBA required the expression of functional SLC5A8, a monocarboxylic acid transporter
(MCT), which is often silenced either through mutations or hypermethylations during
tumor development. Consistent with this, in cells expressing the functional SLC5A8,
significant uptake of 2,4,6-THBA was observed. Additionally, in cells expressing
functional SLC5A8, 2,4,6-THBA induced CDK inhibitory proteins p21Cip1 and p27Kip1 and
inhibited cell proliferation. We also observed that 3,4-DHBA and 3,4,5-THBA were not
taken up by the cancer cells, however, they were very effective in inhibiting cancer cell
growth independent of SLC5A8 expression, suggesting that their targets are most likely
extracellular. These findings, for the first time, demonstrated that the flavonoid metabolite
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2,4,6-THBA may exert its anti-cancer effects through a CDK- and SLC5A8-dependent
pathway, while 3,4-DHBA and 3,4,5-DHBA may exert its anti-cancer effects through a
CDK- and SLC5A8-independent pathway.
Aspirin metabolism has been shown to generate 2,3-dihydroxybenzoic acid (2,3DHBA) and 2,5-dihydroxybenzoic acid (2,5-DHBA). Chapter 4 examines the ability of
these metabolites to inhibit CDKs and cancer cell growth. We demonstrated that
2,3‑DHBA and 2,5‑DHBA inhibits CDK1, CDK2, CDK4 and CDK6 enzyme activity
although the concentrations required significantly varied among different CDK members.
In silico studies were performed to determine the potential sites of interactions of
2,3‑DHBA and 2,5‑DHBA with CDKs. Colony formation assays also showed that
2,5‑DHBA was highly effective in inhibiting clonal formation in HCT‑116 and HT‑29
CRC cell lines and in the MDA‑MB‑231 breast cancer cell line. In contrast, 2,3‑DHBA
was effective only in MDA‑MB‑231 cells. Both aspirin and salicylic acid failed to inhibit
all four CDKs and colony formation in these experiments. Based on the present results, it
is suggested that 2,3‑DHBA and 2,5‑DHBA may contribute to the chemopreventive
properties of aspirin, possibly through the inhibition of CDKs.
Having demonstrated the ability of flavonoid and aspirin metabolites to inhibit CDKs
and cancer cell growth, we attempted to identify the bacterial species involved in its
biotransformation. In chapter 5, we screened 91 human gut bacterial isolates for their
ability to biotransform the flavonoid quercetin into different metabolites under anaerobic
conditions, mimicking the human gut environment. We demonstrated that of the 65 strains
screened, 6 were able to degrade quercetin including Bacillus glycinifermentans,
Flavonifractor plautii, Bacteroides eggerthi, Olsonella scatoligenes, Eubacterium eligens,
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and Lactobacillus spp. Additional studies showed that B. glycinifermentans could generate
2,4,6-THBA and 3,4-DHBA from quercetin, while F. plautii generated DOPAC. In
addition to the differences in the metabolites produced, the kinetics of quercetin
degradation was also different between B. glycinifermentans and F. plautii, suggesting that
the pathways of degradation are likely different between these strains. Investigations into
the bacterial species capable of degrading aspirin was not carried out owing to difficulties
with the detection of the metabolites (2,3-DHBA and 2,5-DHBA) through HPLC.
Summary
The results presented in this dissertation has demonstrated that 2,4,6-THBA generated
from flavonoid biotransformation, and 2,3-DHBA and 2,5-DHBA generated from aspirin
biotransformation are capable of inhibiting CDK enzyme activity and cancer cell growth.
One common property among these metabolites is that all are derivatives of
hydroxybenzoic acids (HBAs). The results obtained from this study suggested that HBAs
may be common mediators of cancer prevention by both flavonoids and aspirin.
Interestingly, these HBAs are also abundantly present in fruits and vegetables as secondary
metabolites produced through the shikimate pathway. Based on the findings obtained from
these studies and previous reports from literature, we propose a novel hypothesis – “the
metabolite hypothesis”, to explain the cancer preventive actions of flavonoids, aspirin, and
a diet rich in HBAs. The metabolite hypothesis proposes that the HBAs produced through
microbial degradation of flavonoids and aspirin or those consumed through the diet may
be common mediators of CRC prevention.
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Significance
The studies described in this dissertation has identified a novel mechanism of cancer
prevention by flavonoids and aspirin through the generation of HBAs. This pathway is
paradoxically different from any of the previously proposed pathways of cancer prevetion
by other investigators. Importantly, the discovery of 2,4,6-THBA, 2,5-DHBA, and 2,3DHBA as inhibitors of CDKS has important implications towards the development of a
novel class of CDK inhibitors which can be used for the prevention of CRC. Additionally,
the identification of the gut bacterial species, B. glycinifermentans and F. plautii, capable
of generating 2,4,6-THBA, 3,4-DHBA and DOPAC, suggests the potential use of these
bacteria as probiotics for the prevention of CRC and also for the general maintenance of
gut health. We believe that these findings are important step forward in decrypting the
complex mechanisms involved in cancer prevention.
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CHAPTER 1: INTRODUCTION
Cancer is an ancient disease or a set of diseases that predates human civilization; its
earliest description can be found in the ancient Egyptian text – the Edwin Smith Papyrus,
dated 3000 BC [1]. This complex disorder evolves in stages that comprise of numerous
transitions within the cell that eventually disrupts the hierarchical organization in
multicellular organisms [2]. Hanahan and Weinberg, in 2000, first described the six
hallmarks of cancer as self-sufficiency in growth signals, insensitivity to anti-growth
signals, limitless replicative potential, evading apoptosis, sustained angiogenesis and tissue
invasion and metastasis [3]. Later in 2011, with increased understanding of the disease,
two more hallmarks were added to this list– deregulating cellular energetics and avoidance
of immune destruction [4]. Our current knowledge of cancer identifies it fundamentally as
a genetic disease whose development can be attributed largely to mutations in
protooncogenes and tumor suppressor genes. Protooncogenes help in the regulation of cell
growth and cellular differentiation. Once mutated, they convert to oncogenes, whose
abnormal expression leads to the transition of a normal cell to a cancerous cell due to
uncontrolled proliferation. Tumor suppressor genes on the other hand prevent the
development of cancer by regulating the over-expression of proto-oncogenes and downregulating aberrantly expressed genes. The inactivation/silencing of tumor suppressor
genes leads to the dysregulation of an important set of genes/proteins that regulate the cell
growth and differentiation across various stages [5]. Genetic alterations in cells can be
attributed to both internal and external factors. Internal factors involve inherited genetic
mutations, epigenetic factors, immune disorders and hormonal imbalance whereas
common external causative agents include exposure to ultraviolet (UV) rays, industrial
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waste, air pollutants, chemical carcinogens, and pathogens like human papilloma virus
(HPV) and Helicobacter pyrolii. In addition, life-style factors such as diet, physical
inactivity, smoking, heavy alcohol use, and obesity also contributes to cancer development.
There has also been a link suggested between the age of an individual and increased cancer
risk owing to epigenetic changes, particularly those that affect the methylation patterns in
tumor suppressor genes and telomerase activity [6].
The process of transformation of a normal cell into a cancer cell (tumorigenesis) is
classified into four stages – (a) Initiation (b) Promotion (c) Progression and (d) Metastasis.
Initiation comprises of genetic alterations or mutation of genes that occur spontaneously or
due to continuous exposure to carcinogens. These mutations are believed to initially arise
in genes affecting biochemical pathways pertaining to cell proliferation, differentiation,
and survival. Promotion comprises of many reversible processes where actively
proliferating, preneoplastic cells accumulate. Progression marks the final stage of
neoplastic transformation, comprising of an increase in tumor size, and further mutations
that increase the invasive potential of these cells. The final stage, metastasis, is
characterized by the spread of cancer cells to other parts of the body through the circulatory
and lymphatic systems (Fig. 1.1) [2, 7]. Cancer has affected millions of people around the
world and the American Cancer Society estimated in 2018 that nearly 17 million people
would be diagnosed globally with this deadly disorder, and it was also predicted that 1.8
million people would be diagnosed with cancer in 2020 in the United States of America
alone; the global cancer burden is expected to reach to 27.5 million new cases by 2040 [8].
Cancer does not discriminate gender and affects men and women of all age groups equally.
It can also arise in any part/organ in the body, however, the three major organs affected by
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cancer include the lungs, breast, and colon [9]. The work presented in this thesis will focus
on colorectal cancer research.

Figure 1. 1: Stages of cancer
Carcinogenesis can be divided into 4 stages – (a) Initiation where a single cell gets
genetically altered either spontaneously or due to exposure to carcinogenic agents; (b)
Promotion where neoplastic cells accumulate, and genetic instability increases; (c)
Progression is marked by increased tumor sized and invasive potential of the cells; and (d)
Metastasis that involves the spread of the cancer cells. Cancer prevention is possible in the
initiation and promotion stages of carcinogenesis.
1.1 Colorectal cancer (CRC)
Colorectal cancer (CRC) is the second most common cause of cancer related deaths
[10, 11] and the third most common cancer diagnosis [12] in the United States of America.
Every year in the United States, around 150,000 cases of CRC is predicted and 1/3rd of
these patients die from this disease. CRC usually begins as a benign adenomatous polyp
that develops into an advanced form of adenoma with high-grade dysplasia, which
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eventually leads to the development of invasive cancer [7]. Formation of benign
precancerous polyps that is characterized by the aggregation of abnormally dividing cells
in the intestinal lumen marks the initiation of CRC. Over time, these polyps gain numerous
mutations and acquire the ability to invade the bowel wall and eventually spread to the
adjacent lymph nodes, and distant metastatic sites. The risk of a polyp developing into CRC
increases with increasing size of the polyps owing to increased accumulation of mutations
and other genetic changes along with epigenetic modifications. As genetic damage
increases over time, features of high-grade dysplasia start to present, and if left untreated,
the polyps will develop the ability to invade adjacent tissues and grow beyond the
confinement of the colon and rectum (Fig. 1.1). Stages 1 and 2 of CRC are usually operable,
through excision of the region containing the tumor(s), while stage 3 has a 73% survival
rate through surgery coupled with adjuvant chemotherapy. Stage 4 CRC is normally
incurable, though life-expectancy can be improved with chemotherapy [7].
1.1.1 Tumor suppressor genes and protooncogenes as drivers of CRC development
Tumor suppressor genes (TSGs) and protooncogenes, following genetic alterations,
are characterized through loss-of-function and gain-of-function effects respectively. These
genetic alterations influence key biochemical pathways involved in growth and
development, contributing to the malignant nature of cancers. More specific to CRC is the
chromosomal instability that results in changes in the chromosomal copy number and
structure. The most commonly encountered chromosomal instability in CRC include the
physical loss of wild type tumor suppressor genes like Adenomatous polyposis coli (APC),
P53 and SMAD4 [13, 14]. CRCs are also characterized by the over-expression of
oncogenes including RAS, BRAF and Phosphatidyl inositol 3 Kinase (PI3K) [15, 16]. Other
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genetic factors that result in the formation of CRC include aberrant regulation of
prostaglandin signaling, and over-expression of epidermal growth factor (EGF) receptors
and vascular endothelial growth factor (VEGF) receptors in the diseased state [17-19].
Recent studies have also indicated a role for epigenetic regulation including global hypomethylation, allele specific hypermethylation, miRNA based genetic regulation and
histone modifications in the pathogenesis of CRC [20, 21]. Additionally, mutations in
DNA-repair genes like MLH1 and MLH2 have also been identified to contribute to CRC
development [22]. All these factors individually or in combination lead to the development
of CRC, and some of the key players in CRC progression are detailed below.
1.1.1.1 APC and development of CRC
Wnt signaling is characterized by the binding of β-catenin (an onco-protein) to
the nuclear transcription factors TCF/LEF, resulting in the expression of growth promoting
genes like c-myc, cyclin D1, matrix metalloproteinase (MMP)-7, and VEGF. Wntsignaling is constitutively activated in progenitor cells of the colorectal epithelium,
whereas in mature/maturing cells this pathway is inactivated by the expression of APC.
APC acts by binding to the excess β-catenin in the cytoplasm, leading to the subsequent
ubiquitination and proteolysis of this onco-protein. Initiation of CRC development is
marked by aberrant activation of the Wnt-signaling pathway that is characterized by the
mutation of the APC gene, rendering it non-functional. This mutation in the TSG tips the
balance to favor uncontrolled proliferation and differentiation of the colonic epithelia [13].
1.1.1.2 Tumor protein P53 (P53) and development of CRC:
The P53 TSG regulates the expression of nearly 150 genes in human cells.
Interestingly, it is mutated in nearly 50% of all cancers, and its inactivation is the second
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key genetic step in CRC development. The mutations include a combination of missense
mutations leading to protein inactivation, and a 17p chromosomal deletion that eliminates
the second P53 allele. In normal cells, P53 is considered as the guardian of the genome
owing to its ability to mediate cell cycle arrest by inducing the CDK-inhibitory protein
p21Cip1 upon exposure of the cells to genotoxic agents. Arresting cell cycle permits the cells
to repair the damaged DNA and prevents accumulation of further mutations. P53 is also
capable of inducing few DNA repair proteins like p48 and P53R2. In cells that contain
extensive DNA damage, P53 can induce pro-apoptotic proteins like Bax, resulting in cell
apoptosis. It has been reported that inactivation of P53 negatively affects its tumor
suppressor functions, and often coincides with the transition of an adenoma to invasive
carcinoma [23, 24].
1.1.1.3 SMAD4 and development of CRC
SMAD4, SMAD2 and SMAD3 are transcription factors that mediates the
transforming growth factor-β (TGF-β) signaling pathway. Once induced by the TGF-β
receptor, the SMAD2/3-SMAD4 complex translocates to the nucleus. In the nucleus, this
heterodimer is responsible for the transcription of numerous proteins involved in cell cycle
arrest and apoptosis. These transcription factors are implicated in the expression of CDK
inhibitors like p15, p21Cip1 and p27Kip1, and are also responsible for the expression of proapoptotic proteins like TIEG, DAPK, GADD45β and Bim, thus contributing to the
regulation of cell growth. Mutations and deletions in SMAD proteins have been shown to
inactivate the TGF-β signaling pathways, contributing to CRC. This mutational
inactivation has been identified as the third step in the progression of CRC and is associated
with the transition from adenoma to high-grade dysplasia or carcinoma [25, 26].
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1.1.1.4 RAS and BRAF and development of CRC
The protooncogenes RAS and BRAF are commonly mutated in CRC patients.
In normal cells, following growth factor stimulation, GTPase activity is elevated through
KRAS leading to the constitutive activation of the serine threonine kinase BRAF. BRAF
activation leads to the downstream stimulation of the Mitogen Activated Protein Kinase
(MAPK) pathway, leading to cellular proliferation. In normal cells, this process is tightly
regulated whereas in cancer cells it is dysregulated due to mutations in RAS and BRAF.
Mutational activation of RAS and BRAF have been shown to occur in 37% and 17% of
CRC cases respectively, which makes these oncogenes important drivers of cancer cell
proliferation. It has been reported that BRAF mutations are detectable in small polyps,
hyperplastic polyps, serrated adenomas and proximal colon cancers as compared to RAS
mutations [27, 28].
1.1.1.5 PI3K signaling and development of CRC
Phosphatidylinositol 3-kinase (PI3K) is an important serine threonine kinase
that feeds into the p42-44 MAPK pathway in cells stimulated with growth factors. Its
temporal activation is critical for cell proliferation. PI3K is a heterodimer that consists of
a regulatory and catalytic subunit – PI3KR and PI3KC respectively. Nearly 1/3rd of CRC
patients have mutations in the catalytic subunit that leads to the constitutive activation of
the enzyme. This in turn results in uncontrolled proliferation, resistance to apoptosis,
angiogenesis and metastasis. Additionally, it is also observed that in some CRC patients
Phosphatase and TENsin homolog (PTEN), a protein involved in PI3K regulation has been
genetically altered either through mutations or deletions, leading to the continuous
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stimulation of this cascade. Interestingly, abnormal activation of PI3K signaling has also
been observed in some CRC patients due to the amplification of the insulin receptor
substrate 2 (IRS2) gene that is upstream of PI3K along with co-amplification of Akt and
PAK4 that are downstream mediators of PI3K signaling [29, 30].
1.2 Cell cycle regulation and cancer development
Cell cycle refers to the process involving the duplication of cellular contents followed
by cell division. One of the hallmarks of cancer is the dysregulation of the cell cycle leading
to uncontrolled cell proliferation [3, 4]. In the human body, cells will not divide unless they
receive a prompt, in the form of a growth signal, from their environment to proliferate.
These signals result in a complex growth cycle, normally referred to as the cell cycle, that
consists of four distinct stages namely G1, S, G2 and M phases, the end of which is marked
by one parent cell dividing into two daughter cells. When cells are in the resting phase
(quiescent phase) and do not divide, it is known as the G0 phase. Each stage of the cell
cycle is tightly regulated by a set of distinct proteins and check points to ensure proper
functioning of the system. The G1 phase is the gap phase between the M phase and the S
phase of the cell cycle, which is marked by doubling in cell size. The restriction check
point at the end of the G1 phase ensures that the environment is favorable for proceeding
into the S-phase. The S-phase or the synthesis phase involves the duplication of the genetic
material and following histone synthesis the cells move into the G2 phase. In the G2-phase,
protein synthesis continues (importantly α- and β-tubulins), microtubules are assembled
and any damage to DNA is rectified and the cells enter mitotic or M-phase. The G2/M
checkpoint blocks the entry of cells into the M phase if DNA replication is incomplete. In
the M phase, the cells finally divide into two daughter cells. The metaphase-anaphase
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transition checkpoint, before the anaphase of the mitotic cycle, blocks the progression of
the anaphase if the chromatids are improperly aligned on the mitotic spindle in the middle
of the cell. Progression of the cell through these stages lead to segregation of the duplicated
chromatids followed by cytokinesis, resulting in the production of two daughter cells [31,
32].
The cell cycle is thus a tightly regulated system, and the progression of this system is
controlled by a subfamily of cyclin dependent kinases (CDKs) that depend on cyclins for
their activation. Each type of cyclin pairs with a specific CDK or a set of CDKs. The D
type cyclins bind to CDK4/CDK6 and regulates the entry and progression of the cell
through the G1 phase of the cell cycle. The E-type cyclins and the A-type cyclins bind to
CDK2 and are involved in part of G1 phase S, and G2 phases. The B-type cyclin binds to
CDK1 and is involved in the M phase of the cell cycle [32].
The activation of CDKs occurs when they bind to their partner cyclins. As the name
suggests, cyclin levels fluctuate throughout the various stages of the cell cycle, resulting in
the periodic activation of CDKs at the necessary phases. CDK levels on the other hand are
constant throughout the entire process. CDKs 1, 2, 4 and 6 are directly involved in the cell
cycle, whereas CDK7 contributes indirectly by acting as a CDK activating kinase (CAK).
Structurally, CDKs are bilobed proteins containing a large flexible loop known as the Tloop or the activation loop that rises from the C-terminal lobe to block the active site and
prevent ATP binding. Hence, CDK activation requires a myriad of structural alterations to
become active [33].
Once the CDK binds to its partner cyclin, it becomes partially activated. This enables
the phosphorylation of the CDK by CAK, on the T-loop at a conserved threonine site. This
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phosphorylation results in complete activation of the CDK and opens the ATP binding
pocket of the enzyme. Once active, the enzyme can phosphorylate its substrate (such as
condensins and lammins for CDK2 and retinoblastoma protein for CDK4 and CDK6) and
bring about the necessary changes for progression of the cell cycle. The activity of these
CDK enzymes are also regulated by Wee1 and Myt1 kinases that inactivate CDKs by
phosphorylating Tyr-15 and/or Thr-16 residues in the CDKs. Dephosphorylation of these
sites by Cdc25 phosphatases can restore kinase activity. Apart from Wee-1 and Myt-1, a
set of CDK inhibitory proteins can bind to either CDK alone or the CDK-cyclin complex
and inhibit CDK activity. These inhibitors fall under the INK4 family or Cip/Kip family
and includes p15, p16, p18, p19 (INK4) that specifically inactivate CDK4 and CDK6 and
p21Cip1, p27Kip1 (Cip/Kip) that can inactivate all CDK-cyclin complexes [34-36]. The
complex regulation of the cell cycle is depicted in Figure 1.2.
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Figure 1. 2: The Cell cycle
The cell cycle is a tightly regulated process in normal cells. The different phases of
the cell cycle (G1, S, G2 and M) are indicated along with their checkpoints (restriction
checkpoint, G2/M checkpoint and Metaphase-Anaphase transition checkpoint). The sites
of actions of CDKs and their binding partners cyclins in each stage of the cell cycle are
also indicated.
1.2.1 Dysregulation of the cell cycle in cancer:
In cancer cells, the process of cell cycle is highly dysregulated due to fundamental
alterations in the genetic control of cell division. This results in uncontrolled cell
proliferation, making it an important hallmark of cancer [3]. As mentioned previously,
genetic alterations occur mainly in protooncogenes and TSGs. While mutations in
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protooncogenes involved in cell cycle regulation (such as EGFR, Src Kinase) promote cell
growth, mutations in TSGs (such as pRB and P53) result in the loss of their ability to inhibit
cell growth, both leading to uncontrolled cell division. Importantly, genetic mutations or
overexpression of proteins have also been observed in other genes that regulate the cell
cycle, contributing to their growth promoting effects. This includes mutations in numerous
CDKs, cyclins, CAKs, CDK substrates, CDK inhibitors (CKI), and checkpoint proteins.
An account of such dysregulated proteins are detailed below:
1.2.2 CDKs
CDKs 1 and 2 are reported to be overexpressed in colon adenomas, and focal
carcinomas in adenomatous tissues [37]. Mutations in CDKs 4 and 6 or their amplification
have been observed in numerous cancers [38]. A study with neuroblastoma cell line
reported that mutations in CDK6 caused a loss of CKI binding, thereby bypassing the cell
cycle block [39].
1.2.3 Cyclins
D-type cyclins are implicated in the regulation of retinoblastoma protein (Rb). In
normal cells, biding of cyclin D to CDK4/6 leads to activation of kinase that phosphorylates
the protein retinoblastoma (Rb) in the Rb-E2F complex. Phosphorylation of Rb results in
the release E2F from this complex. Free E2F, a transcription factor, then helps in the
progression of the cell cycle through G1 phase by upregulating cyclin A1, Cyclin E and
CDK2. Aberrant cyclin D1, D2 and D3 expression has been reported in various human
cancers. Of these, cyclin D1 mutations are more prevalent in cancers of the breast,
esophagus, bladder, lung and also in squamous cell carcinomas [40]. Cyclins E was
reported to be over-expressed in breast and colon cancers and also in acute lymphoblastic
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(ALL) and acute myeloid leukemias (AML). Additionally, cyclins A and E have also been
found to be overexpressed in lung carcinoma [37].
1.2.4 CDK activating enzymes
Cdc25B is a CDK phosphatase that activates CDK by dephosphorylating the CDK
at a site phosphorylated by Wee1 kinase. Over expression of this phosphatase thus leads to
constitutive activation of CDKs, resulting in unrestricted cell proliferation. Overexpression of Cdc25B has been reported in nearly 32% of primary breast cancers. c-myc,
an oncogene associated with numerous human cancers has also been shown to activate
transcription of Cdc25A and Cdc25B. Interestingly, the activation and deregulation of
Cdc25 has also been demonstrated through Raf kinase that is a downstream product of the
RAS protooncogene which is often mutated in cancer [41, 42].
1.2.5 CKIs
p16, p21Cip1 and p27Kip1 proteins are established CKIs that act by clamping on to
either CDKs or CDK-cyclin complexes. The p16 gene is genetically altered in many human
tumors with common alterations including deletions, point mutations and hypermethylations. Deletions of p16 gene has been found in 50% of gliomas and mesotheliomas,
40-60% of nasopharyngeal, pancreatic and biliary tract tumors and 20-30% of ALLs [40,
43]. As p16 targets CDK4/6, inhibition of this protein leads to unhindered progression
through G1 phase of the cell cycle. Loss of p27Kip1 expression has been observed in
colorectal, lung, breast and bladder cancers [37]. Genetic alterations have also been
identified in p21Cip1 protein in some leukemia patients [44, 45].
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1.2.6 CDK Substrates
Rb which is a substrate for CDK4/6 is often mutated in human retinoblastoma and
lung cancers [46, 47]. Common genetic alterations of this protein include deletions and
missense mutations leading a truncated or non-functional form of Rb. Additionally, Rb is
also inactivated in some cells through HPV encoded E7 protein, adenovirus encoded E1A
protein and Simian virus encoded large T antigen. Irrespective of the mechanism, loss of
function of Rb would lead to unrestrained cell cycle progression [48].
1.2.7 Checkpoint proteins
As mentioned above, the TSG P53 is mutated in nearly 50% of all cancers. Point
and missense mutations are frequently observed, leading to changes in the conformation
and inactivation of this protein. Interestingly, HPV encoded E6 protein and adenovirus
encoded E1B-55K protein can also alter or block P53 function [24, 49].
1.3 CDK inhibitors for cancer treatment
Numerous reports have documented the discovery of CDK inhibitors over the past two
decades, owing to the importance of CDKs in cell cycle progression and its dysregulation
in cancers. The very first generation of CDK inhibitory molecules developed were nonspecific in their actions, targeting all CDKs. Hence, they were referred to as pan-CDK
inhibitors. Examples of this class included flavopiridol, olomucine, and roscovitine [50].
Among these, flavopiridol (a semi-synthethic flavonoid) is known to inhibit CDKs 1, 2, 4,
and 6 with IC50 < 200 nM. This compound was capable of inducing cell cycle arrest in G1
and G2 phases and certain studies also showed that it induced cytotoxic responses through
inhibition of CDKs 7 and 9 [51]. Other studies have also shown flavopiridol has diverse
distal cellular effects including transcriptional suppression, apoptosis, autophagy and
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endoplasmic reticulum stress. While flavopiridol had a substantial in vitro inhibitory effect
on CDK activity, it showed considerably diminished activity in vivo against solid tumors.
However, it had potent clinical effects against certain hematological malignancies such as
chronic lymphocytic leukemia (CLL) and mantel cell leukemia and was the first CDK
inhibitor to enter clinical trials. Roscovitine is a purine based CDK inhibitor that was also
tested in clinic. However, the desired therapeutic efficacy was not observed, and all trials
were discontinued [50].
The second generation of CDK inhibitors were designed to be more selective to
individual CDKs and focused on improving the potency of tumor inhibition. Among these,
Dinaciclib is the most extensively studied CDK inhibitor. It had high inhibitory activity
against CDKs 1, 2, 5 and 9 with IC50 values ranging from 1- 4 nM. It also showed inhibitory
effect against CDK 4, 6 and 7 with IC50 values ranging from 60-100 nM. Importantly,
Dinaciclib was effective in inhibiting cell cycle in cancer cell lines isolated from various
tumor types and it caused regression of solid tumors in mouse models [52, 53]. Compared
to flavopiridol, dinaciclib was more effective in tumor suppression. However, it showed
poor or no efficacy in clinical trials for the treatment of solid tumors [50]. The potential
use of Dinaciclib in hematological malignancies is currently being tested in clinical trials.
1.3.1 Targeted inhibition of CDK4 and CDK6
To increase the specificity and efficacy that was not observed in previous CDK
inhibitors, additional inhibitors were developed that targeted unique CDKs. This was
important because the first and second generation of CDK inhibitors were broadly specific
and therefore failed to meet expectations in clinical trials. The failure of these compounds
was attributed to lack of clear understanding of their mechanism of action and low
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specificity that was compounded by their inability to differentiate between cancerous and
normal tissues [50]. As CDK4/6 plays a central role in the first phase of the cell cycle
(G0/G1), efforts were made to identify compounds that targeted these CDKs. The
reasoning was that inhibiting CDK4/6 would arrest cell cycle at G0/G1 phase by preventing
the phosphorylation of Rb and keeping Rb complexed with E2F. Screening of compounds
identified pyrido[2,3-d]pyrimidin-7-one compounds with 2-aminopyridine side chains at
C2 position had high degree of selectivity to CDK4/6. This backbone was utilized to
optimize the drug PD-0332991 (Palbociclib), which could selectively arrest the cells at the
G0/G1 phase in cell culture systems and animal models. The high degree of selectivity
offered by Palbociclib was due to its unique ability to bind to the specialized ATP-binding
pocket of CDK4/6, thereby preventing Rb phosphorylation. This compound is capable of
inhibiting CDK4/6 at nanomolar concentrations and is highly selective compared to a range
of other protein kinases [54]. The food and drug administration (FDA) approved this drug
in the year 2015 for use against metastatic breast cancer. Following this, another CDK4/6
inhibitor was developed – LEE011 (Ribociclib) and this drug has also shown selective
inhibition against CDK4/6 in nanomolar concentrations [55]. Ribociclib was approved by
FDA in 2017 for use against advanced metastatic breast cancer. A third inhibitor –
LY2835219 (Abemaciclib) was also developed to specifically target CDK4/6 and was FDA
approved for use against advanced and metastatic breast cancer in 2017 [56].
The discovery of Palbociclib, Ribociclib and Abemaciclib has ushered a new era of
targeted cancer therapy. While these compounds are in clinical use, they have serious side
effects including neutropenia, and extend the lifespan of the patient for only up to two and
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a half years [57]. This calls for the discovery of additional CDK inhibitory molecules that
are safer to use with lesser side-effects.
1.4 Cancer chemoprevention
In the last decade, due to the increase in occurrences of cancer, the field of
chemoprevention has come to the forefront as the preferred approach to cancer
management. Chemoprevention involves the use of drugs, or other agents to reduce the
risk or delay the occurrence or recurrence of cancer. It is classified into primary, secondary
and tertiary chemoprevention. Primary prevention involves intervening before the onset of
cancer in the general “healthy” population or those at risk for cancer development. This
can be achieved through behavioral changes such as dietary intervention, physical exercise,
smoking cessation, preventing overexposure to the sun, or regular screening and physical
examination, and use of chemical compounds known to reduce the risk of cancer.
Secondary prevention is the intervention before the onset of precancerous processes; this
includes screening individuals with premalignant lesions and administration of anticancerous agents to prevent cancer progression. Tertiary prevention refers to management
of the cancer to slow or stop progression post diagnosis [58, 59].
1.4.1 Drugs as agents of cancer prevention
The FDA approved tamoxifen in 1998 for the prevention of invasive breast cancer
based on the data obtained from the breast cancer prevention trial, which showed a 49%
reduction in invasive breast cancer in more than 13,000 pre- and post-menopausal women
with high risk of developing this disease [60]. Tamoxifen, a selective estrogen receptor
modulator (SERM), is a synthetic drug that has been shown to be effective in preventing
estrogen receptor positive breast cancers. This drug was found most effective in women
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with a known genetic predisposition for BRCA1 and BRCA2 mutations, a history of
lobular carcinoma in situ (LCIS) or atypical ductal hyperplasia [60]. However, the use of
this drug also caused higher incidents of thromboembolic events, and endometrial cancer.
Due to these serious side effects, its use is highly personalized. Raloxifene, another
synthetic and second generation SERM, has similar effects in reducing invasive breast
cancer in high-risk, post-menopausal women. Interestingly, this drug had lower incidences
of thromboembolic events, and endometrial cancers when compared to tamoxifen [61].
Aspirin and other non-steroidal anti-inflammatory drugs (NSAID) have shown
promising anti-cancer effects upon regular consumption for 5 or more years. Aspirin’s
efficacy to reduce CRC is reported to be between 20-40%, and the evidence for this effect
comes from multiple epidemiological and clinical studies which showed that its intake for
5 or more years reduces the risk associated with colorectal adenomas and carcinomas [6265]. This is also supported by animal studies where aspirin has been shown to decrease
chemically induced carcinogenesis in colorectal tissues [66, 67]. These observations and
evidences prompted the United States Preventive Services Task Force (USPSTF), to
recommend “initiating low dose aspirin use for the primary prevention of cardiovascular
disease and colorectal cancer in adults aged 50-59 years” in 2016 [68]. In view of these
compelling evidences, numerous clinical trials have also been launched to address its
efficacy against CRC [63, 69, 70]. Though aspirin has been recommended for the primary
prevention of CRC by the USPSTF, its role in secondary and tertiary prevention has not
been clearly established. Celecoxib, another NSAID that selectively inhibits
cyclooxygenase-2 (COX-2) has also been approved by the FDA for the prevention of
adenomatous polyps in patients with familial adenomatous polyposis (FAP), which is
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associated with the development of colon polyps and a 100% risk for CRC [71]. While
aspirin is recommended by the USPSTF for the prevention of CRC, celecoxib has been
approved only for FAP patients and not the general public by the FDA.
HPV is one of the common causes of uterine cancer, and the vaccines Gardasil and
Cervarix are approved by the FDA as a preventive measure against cervical cancer, precancerous or dysplastic cervical and vaginal lesions, and genital warts associated with HPV
[72]. As mentioned previously, HPV infection in uterine epithelial cells cause inactivation
of Rb and P53 by viral encoded E7 and E6 proteins respectively, leading to uterine cancer.
These vaccines, however, are not approved for the treatment of cervical cancers.
1.4.2 Phytochemicals as agents of cancer prevention
Vitamin A was the first phytochemical compound discovered (in 1976) to possess
cancer chemopreventive properties [73]. Since then, numerous other phytochemicals with
chemopreventive properties have been identified and these include fibers, carotenoids such
as lycopene, other vitamins (C, D, and E), and folate [74]. In addition, studies carried out
in the past two decades have demonstrated that phytochemicals such as flavonoids,
isothiocyanates, glucosinolates, and saponins have anti-tumor properties [75, 76]. The most
prominent among these are the polyphenolic flavonoid compounds present in green and
black tea, fruits, and vegetables such as berries, onions, kale, and grapes to name a few
[77]. Isothiocyanates present in cruciferous vegetables are another class of compounds that
are extensively studied for its anti-cancer properties [78].
The focus of this thesis is to delineate the molecular mechanisms by which
flavonoids and the common household drug aspirin prevent the occurrence of CRC. An
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account of flavonoid’s and aspirin’s anti-cancer properties and known pathways leading to
cancer prevention are detailed below.
1.5 Flavonoids in cancer prevention
Flavonoids are plant secondary metabolites found largely distributed among fruits and
vegetables. They are a major component of the human diet and recent studies have shown
that these compounds could potentially prevent the occurrences of numerous cancers
including those of the colon, breast, and pancreas. The backbone of flavonoids comprises
of an aromatic A-ring bound to a heterocyclic C-ring, which in turn is attached to a third
aromatic B-ring through a carbon-carbon bond (Fig 1.3). More than 4000 types of
flavonoids exist in nature and they are broadly categorized as flavones, flavonols, flavan3-ols (catechins), isoflavones, flavanones, anthocyanins and chalcones depending on the
number and positions of the different functional groups appended or attached to this
backbone (Fig. 1.3). Commonly studied flavonoids include Epigallocatechin gallate
(EGCG), Catechin, Quercetin, Anthocyanins, Genistein, and Kaempferol [79-83].
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Figure 1. 3: Basic backbone (center) and different classes of flavonoids
1.5.1 Flavonoid effects on signal transduction
Clinical and epidemiological studies have largely focused on the ability of flavan3-ols to prevent cancer. Most flavonoids are predicted to prevent the occurrences of cancer
through various mechanisms including antioxidant activity, enzyme/receptor inhibition
properties, regulation of apoptosis and the modification of signal transduction pathways.
EGCG is one of the most well studied flavonoids for anti-cancer effects both in vitro and
in in vivo tumor models. Its interaction with laminin receptor in the extracellular matrix
and insulin like growth factor receptors in the plasma membrane have been implicated in
its role in cancer prevention [84]. It was also demonstrated in human immortalized cervical
cells and cervical tumor cells that ECGC inhibits EGF dependent activation of EGFR, and
subsequent activation of p42/p44 MAPKs, whose activation favors cell proliferation. The
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reduction in p42/p44 MAPK was associated with reduced phosphorylation of downstream
substrates such as p90RSK, FKHR, and Bad as well as increased expression of p21Cip1 and
p27Kip1. This resulted in cell cycle arrest at G0/G1 phases. Importantly, sustained exposure
of cells to EGCG caused cellular apoptosis [85]. In other studies, using LNCaP (androgen
sensitive) and DU145 (androgen insensitive) prostate cancer cells, EGCG caused a
significant dose and time dependent upregulation of p21Cip1, p27Kip1, p16 and p18 CKIs
and downregulation of cyclin D1, cyclin E, CDK2, CDK4 and CDK6 [86]. Another study
demonstrated the ability of EGCG to bind to several target proteins including PI3K, RasGTPase activating protein (GAP) SH-domain-binding protein-1, Bcl/xl and Bcl-2,
vimentin and Fyn, resulting in inhibitory activity against various breast cancer cell lines
and animal models [87].
Another well studied flavonoid compound known for its anti-cancer effects is
Quercetin. It was shown to trigger DNA fragmentation, cleave poly (ADP-ribose)
polymerase, up-regulate Bax and induce post-translational modification of Bcl-2 in human
leukemia cell lines [88, 89]. It has also been recently identified that quercetin enhanced
TRAIL-induced apoptosis by causing the redistribution of Death receptor-4 (DR4) and
DR5 into lipid rafts, demonstrating their synergistic effects on cancer cell apoptosis [90].
Quercetin is also suggested to interact with the androgen receptor LNCaP and/or LAPC-4
to act against prostate cancer [91]. Additionally, it was also shown to be effective against
azoxymethanol induce colonic neoplasia in mice models [92] and also reduced tumor
volume in mice bearing MCF-7 and CT-26 tumors [93].
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There are numerous reports on the effects of flavonols on signal transduction
pathways that include effects on cell cycle regulation, apoptosis, pro-inflammatory protein
induction, and angiogenesis. These effects have been well documented in literature [94].
1.5.2 Antioxidant effects of flavonoids
The antioxidant effects of flavonoids are believed to occur due to the presence of
multiple phenol groups in the ring structure that can scavenge reactive oxygen species
(ROS) including superoxides, singlet oxygen, peroxides and hydroxyl radicals. The
antioxidant properties of anthocyanins have been demonstrated in various cell culture
systems that include colonic, endothelial, leukemic, breast and liver cancer cells. These
studies demonstrated the ability of flavonoids to directly scavenge reactive oxygen species,
increase the oxygen-radical absorbing capacity of cells, reduce the formation of oxidative
adducts in DNA, decrease lipid peroxidation, stimulate the expression of Phase 2 enzymes,
inhibit carcinogen induced mutagenesis and reduce cell proliferation [95, 96].
1.6 Aspirin as a chemopreventive agent
As previously mentioned, aspirin and other NSAIDs have shown promising anti-cancer
effects upon regular consumption for 5 or more years. The first report linking aspirin use
and reduction in CRC was published in 1988 by Kune et al. that showed a statistically
significant reduction in cases taking aspirin-containing medication in both men and women
[97]. An intriguing aspect of aspirin against CRC is its dose independent effect; it is
reported that low-dose aspirin (75-81mg) is as effective in preventing CRC as higher doses
(≥ 325mg) [98]. Multiple mechanisms in cells have been proposed for aspirin’s anticancer
effects and this includes inhibition of enzymes, modulation of signaling pathways and
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transcription factors, and post translational modifications of proteins, although a consensus
has not been reached till date.
1.6.1 Pharmacological effects of Aspirin
Following oral consumption, aspirin is absorbed mainly in the stomach and upper
small intestine [99]; in addition, lymphatic uptake of aspirin has also been recently reported
[100]. Aspirin concentration maximally achieved in the plasma varies depending on the
aspirin dose with anti-platelet (75 mg/day), analgesic (325-600 mg/ 4-6h) and antiinflammatory (1.2 g/4-6h) doses reaching 7.31 μM, 25-80 μM, and 144 μM respectively
[69]. The half-life of aspirin is ~20 min. and it undergoes hydrolysis by intestinal, plasma
and liver esterases to generate salicylic acid [69, 99]. The concentration of salicylic acid in
the plasma has be estimated to be around 15 μM for anti-platelet doses, 500 μM for
analgesic doses and 1.5-2.5 mM for anti-inflammatory doses. The half-life of salicylic acid
is estimated to be 4-6 h in the plasma [69]. It is reported that the oral bioavailability of
aspirin tablets is ~40-50%, while this is significantly reduced (~15 fold) in enteric coated
and sustained release tablets [101]. However, some reports have estimated that aspirin’s
oral bioavailability is ~68% [102].
Aspirin like all other NSAIDs works through the inhibition of COX (COX-1 and
COX-2) enzymes in the body. COX-1 is the only isoform present in mature platelets and
is responsible for platelet aggregation. COX-2 is expressed in many tissues and its
expression is induced in tissues during inflammation, wound healing, and neoplasia [98,
103]. The molecular mechanism of aspirin involves its ability to inhibit arachidonic acid
metabolism through prostaglandin (PG) H synthase or COX pathway. Aspirin inhibits
COX-1 by acetylating Ser530, and acetylates COX-2 at Ser516, thereby inactivating them
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[104-106]. Depending on the cell type, inhibition of COX activity affects synthesis of
different PGs including PGD2, PGE2 and PGF2α, prostacyclin (PGI2) and thromboxane
A2 (TXA2). TXA2 is the major metabolite that promotes the activation and aggregation of
platelets [107]. It is to be noted that aspirin is more selective to COX-1 as compared to
COX-2, with IC50 for COX-1 inhibition observed at 1.7 μM as compared to the >100 μM
required for COX-2 inhibition [108, 109].
1.6.2 Mechanisms proposed for aspirin’s chemo-preventive effects.
As mentioned previously, daily use of aspirin has been shown to reduce the risk of
CRC and recurrence of adenomatous polyps. This observation sparked the interest of
scientists, physicians and public alike for its potential use as a prophylactic drug against
CRC and studies conducted based on this interest has led to numerous hypotheses on its
mechanism of action. Some of the major pathways proposed for its anti-cancer effects are
discussed below.
1.6.2.1 Inhibition of COX enzymes: the platelet hypothesis
Cyclooxygenases are a group of enzymes that are involved in the synthesis of
prostanoids including PGs and TXA2 from arachidonic acid. While TXA2 is majorly
involved in platelet aggregation, PGs such as PGE2 have a role in inflammatory reactions.
Of the two COX enzymes, COX-2 overexpression is associated with cancer progression.
Unlike COX-1 that is constitutively present in all cell types including platelets, COX-2 is
normally absent in many cell types. However, as mentioned above, COX-2 expression is
elevated under inflammatory and other pathological conditions such as cancer [98, 103].
Owing to the involvement of COX-2 in cancer [110] it is suggested that aspirins’ anticancer effects may occur through the inhibition of this enzyme. Additionally, studies
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conducted using COX-1 and COX-2 deletions have also demonstrated reduced intestinal
tumorigenesis [111]. However, a direct inhibition of COX-2 by low-dose aspirin is thought
to be unlikely due to the observed low plasma concentration (~7 μM) and a requirement
for higher amounts for enzyme inhibition (IC50 278 μM) [109]. Thus, the fact that low-dose
aspirin is as effective as higher doses in preventing CRC led to the suggestion that COX-1
inhibition in platelets could indirectly affect COX-2 expression levels in the colorectal
tissues through sequential steps [65, 69, 98].
According to this theory (popularly referred to as the platelet hypothesis) the
initiating event for tumorigenesis in the colorectal tissues is the aggregation and activation
of platelets in the intestinal mucosa upon injury. Persistent activation of platelets, if left
unchecked, will result in the local recruitment of immune cells, leading to inflammation.
Aggregation of platelets at these sites release platelet-derived growth factors (PDGF),
cytokines (interleukin-1β) and lipid mediators (PGE2 and TXA2) that then promote
growth/proliferation of adjacent nucleated cells in the colonic mucosa. It is further
hypothesized that these agents may increase the levels of COX-2 (further increasing PGE2
levels) and result in epithelial–mesenchymal transition (EMT) of the intestinal epithelial
cells, characteristic of early events in tumorigenesis. EMT activation in turn results in the
generation of tumor-initiating cells and triggers tumor cell invasion and metastasis to
distant organs [65, 69, 98]. It is to be noted that, PGE2 binding to EP1-4 receptors (Gprotein coupled receptors) activates signal transduction pathways that promote adhesive,
migratory and invasive behavior of cells during the development and progression of cancer
[18]. Therefore, according to the platelet hypothesis, platelet aggregation and aberrant
activation at site of mucosal injury is the driving factor for the genesis of adenomatous
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polyps and eventual progression to CRC. Aspirin’s chemopreventive effect against CRC
is attributed to its ability inhibit COX-1 in platelets, prevent the release of lipid or protein
mediators of inflammation and subsequently decrease COX-2 expression in colorectal
tissues (Fig. 1.4).

Figure 1.4: Figure legend continued in next page
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Figure 1. 4: The Platelet hypothesis
According to this model, platelet activation and aggregation at the site of
intestinal mucosal injury is fundamental to tumorigenesis in the colorectal tissues.
Activation of platelets can lead to the release of lipid mediators (e.g., PGE2) and
growth factors (e.g., PDGF) from platelets that in turn may promote stromal cell
growth and induce COX-2 expression in intestinal cells of the colonic mucosa. Such
events can further lead to increased PGE2 production resulting in hyperplasia, EMT
and transformation to a neoplastic phenotype [65, 98]. It is hypothesized that central
to the prevention of CRC by aspirin is its ability to prevent platelet aggregation through
inhibition of COX-1 leading to subsequent inhibition of thromboxane A2. Prevention
of platelet aggregation blocks the release of lipid mediators and growth factors from
platelets that induces the expression of COX-2 (in epithelial cells), which is implicated
in tumorigenesis. This hypothesis thus states that sequential inhibition of COX-1 in
platelets followed by inhibition of COX-2 expression in adjacent nucleated cells of the
colorectal mucosa are important steps in aspirin’s cancer preventive actions.
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1.6.2.2 Inhibition of Nuclear Factor (NF)-κB signaling
NF-κB is a transcription factor that is involved in many immune and
inflammatory responses [112]. NF-κB is present as a heterodimer along with IκB in the
cytoplasm. Upon receiving appropriate signals, IκB is phosphorylated by IκB Kinase
(IKK) that eventually leads to the ubiquitin mediated degradation of IκB. The free NF-κB
then translocates to the nucleus where it acts as a transcription factor for many cellular
processes including those that control cellular growth. Aspirin and salicylic acid have been
shown to inhibit IKK, through direct interactions, thus preventing the translocation of NFκB to the nucleus. As aspirin is also an NSAID, it is additionally believed to prevent
inflammation mediated carcinogenesis by affecting this signaling pathway. The effect
exerted by aspirin on NF-κB requires concentrations ranging from 0.05-5 mM [113, 114].
1.6.2.3 Activation of AMP-kinase and inhibition of mTOR signaling
Adenosine monophosphate activated protein kinase (AMPK) is a critical
cellular energy sensor that gets activated in response to stress. AMPK is involved in
processes that synthesize ATP to meet the energy demands of the body. AMPK regulates
numerous pathways including that of P53, fatty acid synthase, and mechanistic target of
rapamycin (mTOR). As these pathways are crucial for cell survival and metabolism,
AMPK has also been implicated in cancer progression in numerous cancers including CRC
[112]. It has been shown that aspirin, at a concentration of 5 mM is capable of decreasing
mTOR signaling by inhibiting the effectors S6K1 and 4E-BP1, that are involved in
translation and protein synthesis, eventually leading to cell death. It was also demonstrated
that aspirin could alter the AMP:ATP ratios in cells, leading to the activation of AMPK,
and subsequent inactivation of mTOR signaling. Aspirin also inhibited mTOR signaling in
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CRC patients treated with analgesic doses (600 mg/day for one week). In these patients,
there was a decreased phosphorylation of S6K1 and S6 effectors, suggesting that their
inhibition helps in the regulation of intracellular energy homeostasis and metabolism,
contributing to the protective effect of aspirin against CRC [115].
1.6.2.4 Inhibition of Wnt signaling and β-catenin phosphorylation
Wnt-signaling is constitutively activated in progenitor cells of the colorectal
epithelium, whereas in mature/maturing cells this pathway is inactivated by the expression
of APC. APC acts by binding to the excess β-catenin in the cytoplasm, leading to the
subsequent ubiquitination and proteolysis of this onco-protein. As mentioned previously,
initiation of CRC development is marked by aberrant activation of the Wnt-signaling
pathway that is characterized by the mutation of the APC gene, rendering it non-functional
[13]. This mutation in the tumor suppressor gene tips the balance to favor uncontrolled
proliferation and differentiation of the colonic epithelia. It has been demonstrated that
aspirin, tested at concentrations between 0.05-5 mM, stimulates the phosphorylation
(through inhibition of protein phosphatase 2A) and subsequent ubiquitination of β-catenin,
leading to the inhibition of the Wnt/ β-catenin pathway [116].
1.6.2.5 Downregulation of c-myc, cyclin A2 and CDK2
c-myc is a nuclear transcription factor that controls 15% of the expression of all
genes. It regulates multiple cellular functions such as cell proliferation, metabolism,
apoptosis, growth and differentiation. It is frequently overexpressed in nearly 20% of all
cancers, and this is associated with poor clinical outcome and an aggressive metastatic
phenotype. Aspirin/Salicylic acid has been shown to downregulate the levels of c-myc
mRNA and protein, between 0.25 and 2.5 mM, in a variety of cancer cells [117], and
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similar results have been reported in another study [118]. Aspirin and salicylic acid have
also been shown to downregulate cell cycle regulatory proteins cyclin A2 and CDK2
through proteasomal mediated pathways at concentrations ranging from 0.5-2.5 mM [119].
It is suggested that this may lead to cell cycle arrest and inhibition of cell proliferation.
1.6.2.6 Induction of polyamine catabolism
Ornithine decarboxylase (ODC) is the first enzyme involved in polyamine
synthesis. The transcriptional regulator c-myc activates the transcription of ODC which
results in increased levels of mucosal polyamines that is implicated in tumorigenesis.
Aspirin use, between 20 and 100 μM, in Caco-2 cells has been associated with the
transcriptional activation of SSAT (spermidine/spermine N1-acetyltransferase), a driver
for polyamine catabolism. Reduced levels of polyamines are thus believed to result in
reduced tumorigenesis [120].
1.6.2.7 Induction of DNA mismatch repair proteins
DNA mismatch repair is a mechanism that is evolutionarily conserved, to repair
mutations that arise during DNA replication or damage. Epigenetic or somatic changes to
mismatch repair genes have been associated with CRC development [121]. It was
demonstrated that in colon cancer cells, exposure of aspirin between concentrations of 110 mM induced DNA mismatch repair proteins by 2-7-fold, depending on the cell line
studied. This in turn was associated with G0/G1 cell cycle arrest and apoptosis. The authors
suggested that, this COX-independent pathway may contribute to aspirin’s anticancer
effects [22].
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1.6.2.8 Acetylation of P53, glucose-6-phosphate dehydrogenase and other proteins
P53 is a tumor suppressor protein that regulates cell proliferation. In normal
cells, it is activated through acetylation and phosphorylation following which it
translocates to the nucleus and acts as a transcription factor. Nearly 50% of all tumors
contain a mutated P53 and such mutations inactivate its tumor suppressor functions leading
to enhanced cell proliferation. Aspirin has been shown to directly acetylate both wild-type
and mutant P53, at concentrations between 0.05 and 2.5 mM, and this was associated with
induction of p21 and Bax, suggestive of a role in restoration of P53 function and tumor
suppression [122-124]. Aspirin was also shown to acetylate glucose-6-phosphate
dehydrogenase (G6PD; at ≥ 100 μM), an enzyme in the hexose monophosphate shunt
pathway and cause decreased enzyme activity. It was suggested that selective inhibition of
G6PD may represent an important mechanism by which aspirin may exert its anticancer
effects through inhibition of ribonucleotide synthesis [125, 126]. Aspirin’s ability to
decrease G6PD, potentially contributing to prevention of cancer cell growth, is an
interesting finding because there are reports that have documented a direct correlation
between G6PD deficiency and decreased cancer incidences [127].
Aspirin also appears to acetylate multiple proteins, over a range of concentrations
starting from 100 μM, in cells grown in culture as well as in vivo [123, 125, 128, 129]. Two
independent reports have documented aspirin’s ability to acetylate multiple proteins which
include histones, cytoskeletal and heat-shock proteins, glycolytic and pentose pathway
enzymes, proteins involved in translation, proteasomal subunits and mitochondrial
proteins. The significance of these post-translational modifications has not been thoroughly
investigated [125, 128]. Interestingly, Tatham et al., reported that although exposure of
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cells to aspirin amplifies the acetylation status of proteins by several orders of magnitude,
protein function is not altered as long as deacetylases are not inhibited. They suggested that
aspirin-mediated acetylations do not possibly accumulate to levels capable of eliciting
biological effects in most cases [129].
1.6.2.9 Other mechanisms
In addition to the pathways mentioned above, aspirin is also known to affect
other targets. For example, it is suggested that aspirin (between 1-4 mM) might exert its
chemopreventive effect against CRC by normalizing EGFR expression in gastrointestinal
precancerous lesions [19]. It is also reported that at concentrations between 0.1-5 mM,
aspirin and salicylic acid could inhibit TPA (12-O-tetradecanoylphorbol-13-acetate)
induced activator protein 1 activity, preventing neoplastic transformation [130]. Another
study showed that aspirin’s ability to inhibit colon cancer cell growth (between 5-10 mM)
may involve downregulation of specificity protein transcription factors [131]. Both aspirin
and salicylate are also reported to induce apoptosis through caspase activation in B-cell
chronic lymphocytic leukemia cells at a concentration of 10 mM [132]. In addition, aspirin
has been shown to exert cytotoxic and anti-cancer effects through generation of reactive
oxygen species in melanoma cells at concentrations between 0.1-1 mM [133]. A recent
study has also demonstrated that low-dose aspirin (100 mg/day for 7 days) causes
acetylation of COX-1, inhibiting PGE2 synthesis, in human intestinal mucosal cells leading
to decreased levels of S6 kinase, suggesting that this pathway may play a role in the
prevention of colorectal carcinogenesis [134]. A compilation of some of these pathways is
diagrammatically represented in Fig. 1.5.
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Figure 1. 5: Other suggested pathways for aspirin’s chemopreventive actions
Aspirin/Salicylic has been shown to modulate a variety of signaling pathways
which may also contribute to its anticancer effects. It is known to inhibit NF-κB pathway,
activate AMPK pathway, inhibit Wnt/β-catenin signaling pathway, cause degradation of cmyc mRNA and proteins, and acetylate P53 leading to induction of p21 and Bax protein
expression, to name a few. See text for details; additional pathways described in the text
are not depicted in this figure. -P, phosphorylated protein; -Ac, acetylated protein.
1.7 Metabolism of flavonoids
The degradation of flavonoids can occur through changes in physical parameters (like
pH) [135], through microbial action in the gut before absorption [136, 137], and through
host metabolism in the liver [138]. It is reported that the absorption of flavonoids is 1%–
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15% in the intestine, and that it is extensively metabolized in the liver through conjugation
reactions for subsequent elimination in the body [139-141]. It is also reported that these
conjugated intermediates may be returned to the intestine through the bile, where it further
undergoes deconjugation, subjecting them to further degradation through microbial
metabolism [137, 142]. As mentioned previously, the basic backbone of flavonoids is
highly conserved and comprises of an aromatic A-ring bound to a heterocyclic C-ring,
which in turn is attached to a second aromatic B-ring (Figure 1.3). The functional groups,
their number and position on this backbone will determine their stability and the
metabolite(s) they generate [143]. Flavonoids are generally stable under acidic conditions
but undergo rapid degradation to simpler phenolic compounds under alkaline conditions
(like in the intestine). Additionally, multiple studies have documented the ability of gut
microbes to degrade flavonoids into simpler phenolic acids, many of which are HBAs. The
most commonly observed HBAs include, 3,4-dihydroxybenzoic acid (3,4-DHBA;
protocatechuic acid), 3,4,5-trihydroxybenzoic acid (3,4,5-THBA; gallic acid), 4hydroxybenzoic

acid

(4-HBA),

2,6-dihydroxybenzoic

acid

(2,6-DHBA),

2,4-

dihydroxybenzoic acid (2,4-DHBA) and 2,4,6-trihydroxybenzoic acid (2,4,6-THBA;
phloroglucinol carboxylic acid) [135-137, 139, 141, 144, 145]. A schematic of the HBAs
generated from flavonoids is shown in Figure 1.6 and 1.7B. Flavonoid degradation also
generates phenolic acids like vanillic acid, caffeic acid and 3,4-dihydroxyphenyl acetic acid
(DOPAC) [145-147].
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Figure 1. 6: Postulated degradation pathways of selected flavonoid compounds to
generate 2,4,6-THBA, 4-HBA, 3,4-DHBA and 3,4,5-THBA
The parent flavonoid compounds (labelled with roman numerals) undergo
autodegradation or microbial degradation to generate unstable intermediates such as
chalcones or depsides which then further degrade to more stable phenolic acids such as 4HBA, 3,4-DHBA, 3,4,5-THBA and 2,4,6-THBA. The chemical structure of the flavonoid
A-ring (labelled within each flavonoid structure) is conserved and generates 2,4,6-THBA.
The flavonoid B-ring (labelled within each flavonoid structure) can generate 4-HBA, 3,4DHBA and 3,4,5-THBA depending on the number of hydroxyl groups. R1, R2 and R3
represent either hydrogen or hydroxyl groups and based on the position and number of –
OH groups in the B-rings flavonoids generate monohydroxy-, dihydroxy- or
trihydroxybenzoic acids [136, 141, 148].
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1.8 Metabolism of aspirin
The reported half-life of aspirin is about 20 min [149] and its metabolism either through
cytochrome P450 (CYP450) catalyzed reactions [150] or direct conjugation of salicylic
acid by phase 2 enzymes [151] in the liver has been well documented. Once absorbed,
intact aspirin is partially hydrolyzed to salicylic acid (half-life is 4–6 h) by esterases in the
blood and liver [152]. Salicylic acid can then be directly excreted (1%–31%) or can be
metabolized in a number of different ways for elimination through kidney or bile. It
undergoes conjugation with glycine to form salicyluric acid which accounts for 20%–65%
of the metabolites generated, whereas ether and ester glucuronides of salicylic acid
constitute 1%–42% of metabolites following conjugation with glucuronic acid [153].
Additionally, CYP450 enzymes in the liver can also metabolize salicylic acid to 2,5dihydroxybenzoic acid (2,5-DHBA; gentisic acid) and 2,3-dihydroxybenzoic acid (2,3DHBA; pyrocatechuic acid) that accounts for 1%–8% of the dose. 2,5-DHBA can further
undergo conjugation with glycine to form gentisuric acid [150]. Aspirin has also been
reported to be metabolized in the gut by the resident microflora. In this regard, Kim et al.
demonstrated the importance of human fecal microbiota to degrade aspirin to salicylic acid
and hydroxylated salicylic acids [154]. They showed that when rats were administered
aspirin along with ampicillin, the bioavailability of aspirin increased when compared to
rats administered with aspirin alone. Supporting this observation, a very recent study by
Zhang et al., in 2019, also showed that administration of aspirin to rats following
amoxicillin treatment decreased aspirin metabolism in the intestine, as compared to rats
treated with aspirin alone [155]. The authors of both studies have suggested an important
role for the intestinal microflora in the biotransformation of aspirin before its absorption
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into circulation. It is also important to emphasize that intestinal epithelial cells also express
CYP450 enzymes [156], although their capability to generate these HBAs is not well
studied. A schematic of the HBAs generated from aspirin is shown in Figure 1.7.

Figure 1. 7: Metabolism of aspirin and flavonoids to generate hydroxybenzoic acids
(A) Aspirin metabolism generates 2,3-DHBA and 2,5-DHBA through CYP450
reactions in the liver [157]. DHBAs have also been shown to be generated through
microbial metabolism of aspirin/salicylic acid [154]. (B) Flavonoid metabolism generates
2,4,6-THBA, 3,4-DHBA, 3,4,5-THBA, 4-HBA, 2,4-DHBA, 2,6-DHBA through microbial
degradation in the intestine [137, 142, 143, 158]. R-R5 represent various functional groups
(example -hydroxy, -ketone, -hydrogen, -methoxy etc.) that are appended/attached to the
flavonoid backbone to generate different groups of flavonoids.
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1.9 Biotransformation of flavonoids and aspirin by the gut microbiota
Following consumption, glycosylated flavonoids can be converted to their aglycone
forms by the host intestinal enzymes such as lactase-phlorizin hydrolase following which
the aglycone is subjected to further metabolism by the intestinal CYP enzymes [159].
Alternatively, other flavonoid-glycosides that cannot be deconjugated by the intestinal
enzymes pass on to the colon where they are biotransformed by the microbial enzymes
[141, 160, 161]. The sugar moieties of these flavonoid-glycones usually serve as the sole
carbon and energy source to the gut microbes following preferential fermentation. Owing
to the anaerobic nature of the intestine, most of the reactions catalyzed by the gut
microbiota rely on reduction and hydrolysis reactions. For flavonoids, these reactions
include ring fission, O- and C-glycosylation, demethylation, dehydroxylation, reduction of
carbon-carbon double bonds, ester cleavage, isomerization, and decarboxylation, to name
a few. Most of these reactions, individually or in combination, lead to the generation of
simpler phenolic acids from the A- and B- rings following the cleavage of the C-ring
including 2,4,6-THBA, 3,4,5-THBA, 3,4-DHBA, 2,5-DHBA, 2,4-DHBA, 2,6-DHBA, 3HBA, 4-HBA, and phloroglucinol [136]. 3,4-DHBA and 3,4,5-THBA are the most
abundant phenols generated from B-ring cleavage and they have been extensively studied
for their therapeutic potential [144, 162-165]. While the biotransformation of flavonoids
has been studied to a certain extent, limited studies exist on the metabolism of aspirin by
intestinal microbiota and this has been mentioned on page 37.
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1.10 Rationale for studies on flavonoid and aspirin metabolites as chemopreventive
agents and the hypothesis
Eradication of cancers in the world requires a three-pronged approach involving
educating the public towards adapting a healthier lifestyle, discovery of drugs to prevent
cancer, and discovery of drugs to treat cancer. Through decades of effort, we have achieved
only one of these milestones as we have many drugs to treat cancer. However, educating
the public to adapt to a healthier lifestyle has only been partially successful, while the
efforts to discover drugs to prevent cancer are lacking. Drugs currently recommended to
prevent cancer, such as tamoxifen and aspirin, were originally meant for the treatment of
other ailments and were repurposed for cancer prevention. The alarming rate at which
cancer is diagnosed every year in the world (which range in millions) suggests that it is
going to be the leading cause of death, surpassing heart disease. So much has been
understood about the risk factors for cancers, molecular mechanisms of cancer initiation
and progression and the mechanisms of drugs that are used in the treatment of cancer. It is
a genetic disease that arises due to mutations in protooncogenes and tumor suppressor
genes and can occur due to sporadic mutations or through hereditary means. Based on
scientific evidence, it is argued that cancer is a preventable disease. Thus, aside from the
treatment options available for cancer, there is an urgent need to raise public awareness
along with discovering chemopreventive agents for the eradication of this deadly disorder.
Synthetic drugs against cancer target different proteins and enzymes within the cells
and often have serious side effects and associated toxicity. One of the reasons for this is
that the human body has not been exposed to these drugs for their efficient metabolism and
elimination, causing collateral damage in normal cells. Therefore, identification of natural
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products or their metabolites for chemoprevention are more appealing as they would be
expected to have less toxicity and side effects. In this context, the demonstration of the
ability of flavonoids and aspirin to prevent CRC interested us to pursue this line of
investigation.
Studies previously performed by Dr. Dachineni in our lab provided the lead for
investigation into the possibility that the metabolites and derivatives of aspirin and salicylic
acid might be important contributors for the prevention of tumorigenesis. As a part of his
research investigation, he demonstrated the ability of aspirin metabolites 2,3-DHBA and
2,5-DHBA, and salicylic acid derivative 2,4,6-THBA to inhibit CDK enzyme activity in
vitro. Interestingly, 2,4,6-THBA is also known to be generated as a metabolite of flavonoid
degradation in the intestine by host microbes. However, the previous studies were limited
in nature and examined the effect of these compounds superficially on CDK enzyme
activity, and a detailed study was not conducted [119, 166]. The unexplored areas include
the effect of these metabolites on cancer cell growth and identification of the bacterial
species that generate these metabolites from flavonoid degradation. The investigation
described in this thesis are therefore an extension of the previous studies on the effect of
these natural compounds on CDKs and how they may contribute to cancer prevention
through inhibition of cell growth. CDKs are often dysregulated and overexpressed in
cancers and therefore are attractive targets for cancer therapy [4]. In this regard, as
mentioned earlier, there are only three FDA approved drugs which act as CDK inhibitors
(Palbociclib, Ribociclib, and Abemaciclib). Therefore, further characterization of these
compounds as CDK inhibitors for potential use in cancer prevention appeared significant.
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This thesis contains four sections – one investigating the effect of 2,4,6-THBA on
CDKs 1, 2, 4 and 6 and its growth inhibitory effects in cancer cells, along with other
flavonoid metabolites, another investigating the ability of aspirin metabolites 2,3-DHBA
and 2,5-DHBA to inhibit these CDKs and cancer cell growth. The third section investigates
the ability of human gut bacterial isolates to biotransform flavonoids and the final section
describes a novel hypothesis (the metabolite hypothesis), based on the results obtained
from this study.
1.10.1 Hypothesis
We hypothesize that flavonoids and aspirin may mediate their anti-cancer effects
through their respective hydroxybenzoic acid (HBA) metabolites, known to be generated
in the gut by bacterial action. Additionally, we hypothesize that the anti-cancer effects of
these metabolites may occur through CDK inhibition.
1.10.2 Approach
The inhibitory effect of the metabolites of flavonoids and aspirin on CDKs were
determined using in vitro CDK assays. The potential interactions of these metabolites with
CDKs were determined by molecular docking studies. The growth inhibitory potential of
these metabolites was tested using various cancer cell lines in vitro, utilizing cell count and
clonogenic assays. Approaches such as qRT-PCR and western blotting was used to
measure the levels of CDK inhibitors upon treatment of cells with HBAs. Uptake of
metabolites into cells were studied using high performance liquid chromatography
(HPLC). Effects of these metabolites on cell cycle progression was determined by flow
cytometry. Identification of bacterial species capable of degrading the flavonoid quercetin
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was performed by screening 94 human gut bacterial strains grown strictly under anaerobic
conditions and the metabolites generated were determined using HPLC.
The investigations carried out in this thesis is the first attempt to understand the
role of HBAs, known to be generated from flavonoids and aspirin, on cancer cell growth.
Our goal in this project was to delineate the mechanistic aspects of CDK inhibition by
HBAs, characterize potential transporters involved in the uptake of HBAs into cells,
identify other molecular events that lead to inhibition of cancer cell growth, and identify
bacterial species involved in the generation of these metabolites.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Materials
100bp DNA ladder [Invitrogen (Carlsbad, CA, USA)]
2,3-DHBA [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
2,4,6-THBA [Sigma Aldrich (St. Louis, MO, USA)]
2,5-DHBA [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
3,4,5-THBA [Sigma Aldrich (St. Louis, MO, USA)]
3,4-DHBA [Sigma Aldrich (St. Louis, MO, USA)]
P γ-ATP [MP Biochemicals (Solon, OH, USA)]
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P γ-ATP [PerkinElmer (Waltham, MA, USA)]
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4-HBA [Sigma Aldrich (St. Louis, MO, USA)]
6X DNA loading dye [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Acetonitrile [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Agarose [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Aluminum potassium sluphate (AlK(SO4)2 (anhydrous)) [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
Ammonium acetate [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Ammonium chloride (NH4Cl) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Ammonium Persulfate [Biorad laboratories (Hercules, CA, USA)]
Annexin V/7-AAD kit [Beckman Coulter (Miami, FL, USA)]
Aspirin [Sigma Aldrich (St. Louis, MO, USA)]
β-mercaptoethanol [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Biotin [Sigma Aldrich (St. Louis, MO, USA)]
Boric acid (H3BO3) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Bovine Serum Albumin (BSA) Heat shock fraction [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
Bradford’s reagent [Biorad laboratories (Hercules, CA, USA)]
Brain Heart Infusion (BHI) Broth [Sigma Aldrich (St. Louis, MO, USA)]
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Bromophenol blue [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Calcium chloride (CaCl2 (anhydrous)) [Thermo Fisher Scientific Inc., (Waltham, MA,
USA)]
Calcium chloride dihydrate (CaCl2.2H2O) [Thermo Fisher Scientific Inc., (Waltham, MA,
USA)]
Calcium Pantothenate [Sigma Aldrich (St. Louis, MO, USA)]
Chloroform [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Cobalt nitrate hexahydrate (Co(NO3)2.6H2O) [Thermo Fisher Scientific Inc., (Waltham,
MA, USA)]
Coomassie stain [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Copper (II) sulphate pentahydrate (CuSO4.5H2O) [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
Crystal violet [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
D-glucose [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Dimethylsulfoxide (DMSO) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Dithiothretiol (DTT) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
DNase I [Invitrogen (Carlsbad, CA, USA)]
Doxycycline [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Ethanol [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Ethyl acetate [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Ethylenediaminetetraacetic acid [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Folic acid [Sigma Aldrich (St. Louis, MO, USA)]
Glycerol [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Glycine [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
H1 Histones [EMD Millipore (Billerica, MA, USA)]
Hemin [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Histidine [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Immobilon membranes [EMD Millipore (Billerica, MA, USA)]
Iron (II) sulphate heptahydrate (FeSO4.7H2O) [Thermo Fisher Scientific Inc., (Waltham,
MA, USA)]
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Isopropyl alcohol [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
L-cystein [Sigma Aldrich (St. Louis, MO, USA)]
Magnesium Chloride [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Magnesium chloride hexahydrate (MgCl2.6H2O) [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
Magnesium sulphate heptahydrate (MgSO4.7H2O) [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
Manganese sulphate monohydrate (MnSO4.H2O) [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
Menadione [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Methanol [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Monopotassium phosphate [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
MOPS (3-(N-morpholino) propanesulfonic acid) [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
n-butanol [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Nickel chloride hexahydrate (NiCl2.6H2O) [Thermo Fisher Scientific Inc., (Waltham, MA,
USA)]
Nicotinic acid [Sigma Aldrich (St. Louis, MO, USA)]
p-Aminobenzoic acid [Sigma Aldrich (St. Louis, MO, USA)]
Phosphate buffered saline (PBS) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Potassium dihydrogen phosphate (K2HPO4) [Thermo Fisher Scientific Inc., (Waltham,
MA, USA)]
Potassium Sulphate (K2SO4) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Protease inhibitor tablets [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Pyridoxine hydrochloride [Sigma Aldrich (St. Louis, MO, USA)]
qPCR reagents [Applied Biosystems (Foster City, CA, USA)]
Quercetin [Sigma Aldrich (St. Louis, MO, USA)]
Resazurine [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Riboflavin [Sigma Aldrich (St. Louis, MO, USA)]
RT-PCR reagents [New England Biolabs (Ipswich, MA, USA)]
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Salicylic acid [Sigma Aldrich (St. Louis, MO, USA)]
Sodium Acetate (CH3COOH) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Sodium bicarbonate (NaHCO3) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Sodium Chloride (NaCl) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Sodium dodecyl sulphate (SDS) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Sodium hydroxide (NaOH) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Sodium molybdate dihydrate (Na2MoO4.2H2O) [Thermo Fisher Scientific Inc., (Waltham,
MA, USA)]
Sodium selenite (Na2SeO3) (anhydrous) [Thermo Fisher Scientific Inc., (Waltham, MA,
USA)]
Sodium tungstate dihydrate (Na2WO4.2H2O) [Thermo Fisher Scientific Inc., (Waltham,
MA, USA)]
Super Signal™ West Pico Chemiluminescent Substrate [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
Thiamine [Sigma Aldrich (St. Louis, MO, USA)]
Thioctic acid [Sigma Aldrich (St. Louis, MO, USA)]
Tricine [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Tris-base [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
TRIzol reagent [Invitrogen (Carlsbad, CA, USA)]
Trypan blue [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
trypsin-EDTA [Sigma Aldrich (St. Louis, MO, USA)]
Tween 20 [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Tween 80 [Sigma Aldrich (St. Louis, MO, USA)]
Vitamin B12 [Sigma Aldrich (St. Louis, MO, USA)]
Yeast extract [Sigma Aldrich (St. Louis, MO, USA)]
Zinc sulphate heptahydrate (ZnSO4.7H2O) [Thermo Fisher Scientific Inc., (Waltham, MA,
USA)]
ZORBAX C-18 column [Agilent technologies (Santa Clara, CA, USA)]
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2.2 Buffers
4X Protein dye: 20% SDS (4 ml); 2M Tris.Cl (pH 6.8); Glycerol (8 ml); Bromophenol blue
(40 mg) and β-mercaptoethanol (200 μl/ml).
10X Running buffer: Tris base (30 g); Glycine (144); SDS (10 g); make up to 1 L with
water.
Lysis buffer: 1M Tris.Cl (pH 7.4) – 2ml; 4M NaCl (3.75 ml); Glycerol (15 ml); Triton X100 (1 ml); make up to 100 ml with water.
Protein transfer buffer: Tris base (11.6 g)l Glycine (5.85 g); Methanol (500 ml); make up
to 2 L with water.
Washing buffer: 1M Tris.Cl (pH 7.4) – 20 ml; NaCl (11.5 g); Make up to 2 L with water;
Tween 20 – 1 ml.
2.3 Cell lines, culture media and other reagents
HCT-116, HT-29 and Caco-2 (Human colon cancer cells) from ATCC (Manassas, VA,
USA)
MDA-MB-231 (Human breast cancer cells) from ATCC (Manassas, VA, USA)
MDA-MB-231 cells expressing functional SLC5A8 (SLC5A8-pLVX cell line) was kindly
provided by Dr. Puttur Prasad, Medical College of Georgia.
RPMI 1640 media (for both the MDA-MB-231 cell lines) [Thermo Fisher Scientific Inc.,
(Waltham, MA, USA)]
McCoy’s 5A media (for all other cell lines) [Thermo Fisher Scientific Inc., (Waltham, MA,
USA)]
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Fetal Bovine Serum (FBS) [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
Penicillin-streptomycin antibiotics [Thermo Fisher Scientific Inc., (Waltham, MA, USA)]
2.4 Recombinant proteins and antibodies
anti-p21Cip1, anti-p27Kip1, anti-CDK1, anti-CDK2, anti-CDK4, anti-cyclinA2, anticyclinB1, anti-cyclinD1, and anti-β tubulin antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA); anti-SLC5A8 from Invitrogen (Carlsbad, CA, USA);
goat anti-rabbit and goat anti-mouse antibodies were obtained from Bio-Rad (Hercules,
CA, USA). CDK1/Cyclin B1, CDK2/Cyclin A2, CDK4/Cyclin D1, Retinoblastoma (Cterm) and kinase buffer were purchased from SignalChem (Richmond, BC, Canada).
2.5 Cell culture
MDA-MB-231 cells were grown in RPMI media while HCT-116 and HT-29 cells were
cultured in McCoy’s 5A media, both supplemented with 10% FBS and antibiotics for 24h
before treatment with specified compounds for indicated times; all cell lines were
maintained at 37 °C and 5% CO2. SLC5A8-pLVX cells were grown in the presence of
doxycycline (5μg/ml) for the induction of SLC5A8. Authentication of cell lines was done by
ATCC through their DNA-STR profile.
2.6 Cell lysate preparation and Western Blotting
Following treatment with compounds at the specified concentrations, cells were
washed with 1X PBS and lysates were prepared as previously described [117]. Fifty
micrograms of total protein was separated on an 8 or 12% polyacrylamide gel, transferred
to immobilon membrane and immunoblotted with indicated antibodies.
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2.7 In vitro CDK assay
In vitro CDK assays, to measure enzyme activity, were performed as described by the
manufacturer [167-170] and previously published protocols [119, 166, 171]. Briefly,
purified enzyme was aliquoted into the reaction buffer and incubated with indicated
compounds (aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA) at various concentrations
for 10 min. at room temperature. The reaction mixture was incubated with kinase buffer
containing 15 µM ATP, 2 µCi of [32P] γ-ATP, 5 µg of H1 Histone (7.5 μg/reaction added
as substrate for CDKs 1 and 2) or retinoblastoma (1.5 μg/reaction added as substrate for
CDKs 4 and 6), at 30°C for 20 min in a final volume of 50 μl. The reactions were halted
by adding EDTA to a final concentration of 20 mM and addition of 4X loading buffer. The
samples were boiled for 10 min, analyzed by 8 or 10% SDS-PAGE, stained using
coomassie brilliant blue (R250) to confirm equal loading of the H1 histones and
Retinoblastoma protein. The molecular weight of the proteins was confirmed by molecular
weight markers. The gel was dried and exposed to X-ray film. NIH ImageJ software was
used to quantify the intensities of the bands. The normalization of the band intensities of
the phosphorylated H1 histones/ Retinoblastoma proteins were determined by comparing
to the control, which is the phosphorylation in the absence of these compounds.
2.8 Molecular docking studies
The crystallographic three-dimensional structures of CDK1 (4Y72 A chain), CDK2
(1FIN A chain) and CDK4 (3G33 A chain) were retrieved from the Protein Data Bank
(PDB). Energy minimization for these proteins was performed using Gromacs 3.3.1
package utilizing GROMOS96 force field[172]. The energy-minimized molecules were
used as the receptors for virtual small molecule docking with 2,4,6-THBA, 3,4-DHBA,
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3,4,5-THBA, 4-HBA, phloroglucinol, aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA
using AutoDockVina. The results were visualized by PYMOL molecular graphics system
version 1.3.
2.9 HPLC analysis for detection of metabolites from cancer cell lysates
High Performance Liquid Chromatography (HPLC) was utilized to determine the
uptake of flavonoid metabolites. Cells were exposed to different compounds at indicated
concentrations and lysates were prepared as described previously[166]. Protein
concentration was determined; 300μl of the lysates were taken and proteins were
precipitated using 15μl of trifluoroacetic acid (TFA). Samples were centrifuged at
14,000rpm for 5 min, the supernatant was transferred to fresh tubes and the pH was
adjusted to about 4-5. Finally, 300μl of acidified methanol was added to the samples. HPLC
analysis was conducted using a Waters HPLC system equipped with a 1525 binary pump
and a W2998 PDA detector. An isocratic method was used to elute the compound in reverse
phase using an Agilent ZORBAX (SB-CN, 5µm, 4.6×250mm) column. The mobile phase
contained 20mM ammonium acetate (adjusted to pH 4.0 with acetic acid) and methanol
(90:10 ratio), with a flow rate of 0.7 ml/min. The injection volume was 40l. Compounds
were detected at a wavelength of 260nm. Quantification was done by generating a standard
graph using known amounts of each compound.
2.10. RNA isolation and qRT-PCR
Total RNA was isolated from treated and untreated cells as previously described
using TRIzol reagent[124]. RT-PCR was performed according to the manufacturer’s
instructions (NEB). Briefly, total RNA from 2,4,6-THBA treated cells were isolated and
reverse transcribed for 1h at 42°C using M-MuLV reverse transcriptase followed by
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amplification of the cDNA product. The qPCR experiment was set by adding equal
volumes of each template to the SYBR Fast Master mix along with ROX dye (Applied
Biosystems)

and

5pmols

AGCTCAATGGACTGGAAGG

of
Reverse:

each

primer

(p21Cip1

TGGATGAGGAAGGTCGCT;

Forward:
p27Kip1

Forward: GCTGAGGAACTGACGTGG Reverse: AGGGCAGTGAGGATAGGT). The
final volume was adjusted to 20µl using nuclease free water (NEB) and the reaction
mixture was amplified through one cycle of 50°C for 2 min, 95°C for 2 min; 40 cycles of
95°C for 15 sec, 60°C for 1 min and 72°C for 1 min; and one melt cycle of 95°C for 15
sec, 60°C for 1 min and 95°C for 15 sec. GAPDH was used as internal control for the qPCR
reaction

(Forward:

CCACTCCTCCACCTTTGAC

Reverse:

ACCCTGTTGCTGTAGCCA).
2.11 Flow cytometric analysis
SLC5A8-pLVX cells were treated for 72h with varying concentrations of 2,4,6THBA. Adherent cells were collected by trypsinization and pooled with floating cells,
washed with 1X PBS. Cell cycle analysis was performed by adding Vybrant® DyeCycle™
Green Stain at a final concentration of 250nM to 1ml cell suspension. The samples were
analyzed by flow cytometry following incubation for 30 min at 37°C. To detect apoptosis,
cells were stained with an Annexin V/7-AAD kit as previously described[173]. All
experiments were carried out by the CytoFLEX flow cytometer (Beckman Coulter) using
CytExpert 2.0 software.
2.12 Clonogenic assay
Clonogenic assays were performed as previously described[174]. Cells were seeded
at a density of 500 cells/100mm plate and grown for 48h following which specified
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compounds were added at the concentrations indicated. The spent media was replaced with
fresh media containing the respective compounds every 5-6 days. Cells were incubated for
14-21 days, fixed with 100% methanol for 20 min, and stained with 0.5% crystal violet
prepared in 25% methanol. The colonies were then photographed and quantified using NIH
ImageJ software.
2.13 Cell proliferation analysis through cell counting
Approximately 250,000 cells were seeded per 100 mm plates containing 10% FBS
and grown overnight. Cells were left untreated (control) or were treated with drugs at
various concentrations and incubated for 48 hours. The floating cells in the spent media (if
any) were collected, pooled with the trypsinized cells, and counted using the Nexcelom
Cellometer Auto T4 cell counter.
2.14 Bacterial culture medium
Modified Brain Heart Infusion (mBHI) broth was prepared as described by Ghimire
et al [175] with minor modifications and this media was used as a base medium for growing
the strains. Briefly, yeast extract (5.0 g/L), L-cysteine (0.3 g/L), 1 ml/L resazurine (0.25
mg/ml) and 1 ml/L menadione (5.8 mM) was added to the standard BHI base ingredients.
The prepared media was purged with nitrogen gas until it became completely anaerobic.
The medium was then autoclaved at 121°C and 15 psi for 30 min. The sterilized medium
was then supplemented with 1 ml/L of hemin solution (0.5mg/ml), 10 ml/L of ATCC
vitamin mixture (ATCC, USA), and 10 ml/L of ATCC mineral mixture (ATCC, USA).
For experiments studying quercetin degradation, 7N minimal media was used as
described by Rodrigus-Castano et al. [176], with slight modifications. Briefly, 50 mM
MOPS⋅NaOH (pH 7.2), 0.02% resazurin, 2 mM tricine, 0.025% tween-80, 20 mM
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CH3COONa, 20 mM NaCl, 14 mM NH4Cl, 0.25 mM K2SO4, 0.5 mM MgCl2⋅6H2O, 0.5
mM CaCl2⋅2H2O, 10 μM FeSO4⋅7H2O, 20 mM NaHCO3, 1 mM KH2PO4, 1 μg/ ml
menadione, 1.9 μM hemin, 0.2 mM histidine, 8 mM L-cysteine, and 40 mM D-glucose
were added, and the prepared media was purged with nitrogen until it became completely
anaerobic. Following this, the media was supplemented with 1 × ATCC trace minerals and
1 × ATCC vitamin supplements. The media was then filter-sterilized (0.22 μm pore
diameter). Quercetin was dissolved in ethanol (75mg/ml) and added to this media to obtain
a final concentration of 75 µg/mL to give 7NQ media.
2.15 Screening for bacterial species that were capable of metabolizing quercetin
We first analyzed 57 human fecal isolates from the human gut bacterial library [175]
for their ability to grow in 7NQ media. Briefly, the liquid culture of each strain was adjusted
to an O.D.600 of 0.5 and 20µL of this culture was inoculated into 1ml of 7NQ media. The
bacterial culture was then grown for 48h anaerobically. Following incubation, the O.D.600
of the strains were measured and compared to their growth in 7N media. HPLC was
performed to analyze the ability of the tested bacteria to degrade quercetin.
2.16 HPLC analysis for the detection of quercetin/ metabolites in bacterial culture
supernatant
High Performance Liquid Chromatography (HPLC) was utilized to determine the
concentration of quercetin in the samples. 7NQ media and ethyl acetate was taken in a ratio
of 1:2 and the samples were vortexed thoroughly following which phase separation was
achieved by centrifuging the samples at 14000rpm for 5 mins. The organic phase was
aspirated to a fresh tube and was dried under a steady stream of Argon gas. Following this,
400μL of the mobile phase was added to the dried samples and vortexed to mix the
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contents. The samples were centrifuged at 14000 rpm for 5 min to pellet any debris and the
supernatant was subjected to HPLC analysis. HPLC analysis was conducted using an
Agilent HPLC system equipped with PDA detector. An isocratic method was used to elute
the compound in reverse phase using an Agilent ZORBAX (5µm, 4.6×250mm) column.
The mobile phase for quercetin detection consisted of acetonitrile and 2% acetic acid
(40:60 ratio), with a flow rate of 0.8 ml/min. The injection volume was 40µl. Quercetin
was detected at a wavelength of 370nm. Quantification was done by generating a standard
graph using known amounts of quercetin.
The metabolites of quercetin degradation were extracted with double the volume of nbutanol from the spent media. The n-butanol extract was dried under a steady stream of
argon gas and the dried samples were dissolved in the mobile phase. The mobile phase for
metabolite detection consisted of acetonitrile and 30mM ammonium acetate [pH 4.0;
89:11(v/v)]. This solution was added to methanol at a ratio of 80:20 ratio. The HPLC
apparatus and column used was the same as that used for quercetin detection. The flow rate
for the method was maintained at 0.8 ml/min. The injection volume was 40µl. 2,4,6-THBA,
3,4-DHBA and DOPAC was detected at a wavelength of 270nm. Quantification was done
by generating a standard graph using known amounts of each metabolite.
2.17 Lysis of bacteria and assay for determination of quercetin degrading enzyme
activity
Bacterial cell lysates were prepared as described previously with minor modifications
[177]. Briefly, cells were inoculated in 7N (control) and 7NQ media to an O.D.600 of 0.05
and were then cultivated anaerobically at 37 °C for 24 h. The cells were then harvested,
washed twice with buffer A (50 mM Tris-Cl pH 7.5, 20 mM NH4Cl, 1% v/v glycerol, and
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100 mM NaCl), and then lysed by suspension in buffer A containing 0.5 mg/ml of
lysozyme and 2 units/ml of DNase I followed by incubation at 37 °C for 20 min with
occasional vortexing. The cell suspension was then centrifuged at 17,000 xg for 30 min
and the supernatant was recovered as the crude lysate.
Quercetin degrading enzyme activity was analyzed by measuring the decrease in the
absorbance of the reaction mixture at 367nm as previously described [177]. Each reaction
was set up as follows: 30 µl of 45mM quercetin dissolved in DMSO was added to 870 µl
of 50 mM Tris-Cl buffer (pH 7.5) and preincubated for 5 min. The enzymatic reaction was
started by adding 100 µl of either the spent culture supernatant or the cell lysate and the
absorbance was recorded at 367 nm following 2 min incubation at 25°C. The molar
extinction coefficient was calculated using the blank samples under the same conditions as
the reaction mixture.
2.18 Statistical analysis
All experiments were repeated 3-6 times independently of each other. One-way
ANOVA followed by Tukey’s post-hoc tests were adopted to compare group differences
to control and significance was defined as p<0.05.
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CHAPTER 3: THE FLAVONOID METABOLITE 2,4,6-TRIHYDROXYBENZOIC
ACID IS A CDK INHIBITOR AND AN ANTI-PROLIFERATIVE AGENT
3.1 Abstract
Flavonoids have emerged as promising compounds capable of preventing colorectal
cancer (CRC) due to their antioxidant and anti-inflammatory properties. It is hypothesized
that the metabolites of flavonoids are primarily responsible for the observed anti-cancer
effects owing to the unstable nature of the parent compounds and their degradation by
colonic microflora. In this study, we investigated the ability of one metabolite, 2,4,6trihydroxybenzoic acid (2,4,6-THBA) to inhibit Cyclin Dependent Kinase (CDK) activity
and cancer cell proliferation. Using in vitro kinase assays, we demonstrated that 2,4,6THBA dose-dependently inhibited CDKs 1, 2 and 4 and in silico studies identified key
amino acids involved in these interactions. Interestingly, no significant CDK inhibition was
observed with the structurally related compounds 3,4,5-trihydroxybenzoic acid (3,4,5THBA) and phloroglucinol, suggesting that orientation of the functional groups and
specific amino acid interactions may play a role in inhibition. We showed that cellular
uptake of 2,4,6-THBA required the expression of functional SLC5A8, a monocarboxylic
acid transporter (MCT). Consistent with this, in cells expressing functional SLC5A8, 2,4,6THBA induced CDK inhibitory proteins p21Cip1 and p27Kip1 and inhibited cell proliferation.
These findings, for the first time, suggest that the flavonoid metabolite 2,4,6-THBA may
mediate its effects through a CDK- and SLC5A8-dependent pathway contributing to the
prevention of CRC.
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3.2 Background and hypothesis
The goal of this study was to determine the ability of 2,4,6-THBA, generated from the
flavonoid A-ring, to inhibit CDK activity and cancer cell growth. Two important
observations previously reported by us on 2,4,6-THBA led to the present study. First, while
determining the ability of salicylic acid derivatives (2,3-dihydroxybenzoic acid and 2,5dihydroxybenzoic acid) to inhibit CDK enzyme activity, we observed that 2,4,6-THBA
also inhibited its activity in vitro [166]. Secondly, among all the hydroxybenzoic acids
(HBAs) tested in that study, 2,4,6-THBA exhibited the highest level of CDK inhibition
which prompted us to further examine its potential to inhibit cancer cell growth. CDKs are
often dysregulated and overexpressed in cancers and therefore are attractive targets for
cancer therapy [178]. The present investigation was carried out to study 1) the effect of
2,4,6-THBA on CDKs 1, 2 and 4; 2) the interactions of 2,4,6-THBA with CDKs though in
silico analysis; 3) to identify a transporter for its cellular uptake; and 4) its ability to inhibit
cell proliferation in colon cancer cell lines. In this study we demonstrate that 2,4,6-THBA
dose-dependently inhibits activities of CDKs 1, 2 and 4, and identify the specific amino
acids involved in these interactions. We show that SLC5A8, a member of the
monocarboxylic acid transporter (MCT) family, is required for the cellular uptake of 2,4,6THBA. In cell lines ectopically expressing SLC5A8, 2,4,6-THBA induced the expression
of CDK inhibitors p21Cip1 and p27Kip1 (mRNA and protein) and this was associated with
decreased cell proliferation. Interestingly, the other two metabolites, 3,4-DHBA and 3,4,5THBA, which failed to inhibit CDK activity, potently inhibited cancer cell proliferation
independent of a functional SLC5A8. These results suggest that the flavonoid metabolite
2,4,6-THBA may mediate its anti-cancer effects through a CDK- and SLC5A8-dependent
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pathway, whereas 3,4-DHBA and 3,4,5-THBA are likely to exert their effect through a
CDK- and SLC5A8-independent pathway.
3.3 Results:
3.3.1 Dose dependent effect of 2,4,6-THBA on CDK 1, 2 and 4 enzyme activity
In a previous report, we showed that 2,4,6-THBA inhibits CDK1 activity in vitro;
however, a detailed study of its effects on other CDKs or its biological implications was
not investigated [166]. We, therefore, initiated this study by analyzing the dose-dependent
inhibitory effect of 2,4,6-THBA on recombinant CDKs 1, 2 and 4. Figure 3.1A-C (upper
panel) shows the effect of 2,4,6-THBA on CDK1, 2 and 4 enzyme activity over a range of
concentrations (62.5µM to 1mM for CDK1 and 2; and 125µM to 1mM for CDK4). The
quantified data representing the degree of inhibition is shown in the lower panel. The IC50
of 2,4,6-THBA was 580±57µM for CDK1, 262±29µM for CDK2 and 403±63µM for
CDK4. These experiments also revealed that 2,4,6-THBA was most effective against
CDK2 as compared to CDKs 1 and 4. The middle panels of Fig. 3.1A-C show that each of
the lanes contain similar levels of the substrate. In a separate experiment, we also tested
the inhibitory effect of 2,4,6-THBA on CDK6 activity; however, owing to the
inconsistency in the obtained results, these data are not reported.
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Figure 3. 1: Dose dependent effect of 2,4,6-THBA on different CDKs
A, B, and C show the dose dependent effects of 2,4,6-THBA on CDK1, CDK2 and
CDK4 enzyme activity respectively. H1 histones were used as the substrate for CDK1 and
CDK2, while retinoblastoma protein was used as the substrate for CDK4. Upper panel
shows phosphorylation of H1 Histones (CDK1 and CDK2) and Retinoblastoma protein
(CDK4) in the presence of different concentrations of 2,4,6-THBA. The middle panel
shows the Coomassie blue stained proteins. Lower panel represents the quantification of
the bands in upper panel.
3.3.2 Comparison of the effect of 2,4,6-THBA, phloroglucinol and 3,4,5-THBA on
CDK enzyme activity
To investigate the importance of the carboxyl (-COOH) and hydroxyl (–OH)
functional groups and their positions within the aromatic ring, two structurally related
compounds, phloroglucinol and 3,4,5-THBA (gallic acid), were tested for their effect on
CDK activity and compared against 2,4,6-THBA at a concentration of 500µM. As shown
in Fig. 3.2, 2,4,6-THBA inhibited the activity of all three CDKs confirming the results
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obtained in Fig. 3.1A-C. Interestingly, 3,4,5-THBA had a marginal effect, if any, on CDK1
and CDK4 and failed to inhibit CDK2, whereas phloroglucinol which lacks a –COOH
group had no effect on CDK4 but slightly inhibited CDK1 and 2 (Fig. 3.2 lower panel).
These results suggest that the presence of a –COOH group and the relative positions of the
–OH groups on the benzene ring are important for exhibiting effective CDK inhibition.

Figure 3. 2: Comparison of the effect of phloroglucinol, 2,4,6-THBA and 3,4,5-THBA
on CDK1 (A), CDK2 (B) and CDK4 (C) activity
Upper panel shows phosphorylation pattern of H1 Histones (CDK1 and CDK2) and
Retinoblastoma protein (CDK4), in the presence of different compounds. The middle panel
shows Coomassie blue stained proteins. The lower panel shows quantification of the blots
in the upper panel.
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3.3.3 Molecular docking studies show potential interactions of 2,4,6-THBA,
phloroglucinol and 3,4,5-THBA with CDKs
AutoDock Vina was used to predict the potential interactions of 2,4,6-THBA, 3,4DHBA, 4-HBA, phloroglucinol and 3,4,5-THBA with CDKs 1, 2 and 4. The binding free
energy and hydrogen bond lengths were also determined. The results of the docking studies
are shown in Table-3.1 and Fig. 3.3A-C (space-filling model). The active site of the widely
studied CDK2 enzyme has a total of 16 amino acids (Ile10, Gly11, Glu12, Val13, Val64,
Glu81, Phe82, Leu83, Asp86, Asp127, Lys129, Gln131, Asn132, Leu134, Asp145,
Thr165) [179]. All the compounds tested interacted with CDKs (except 4-HBA and CDK1)
and utilized amino acids either residing in the active site or at alternate binding pockets.
Docking studies revealed that 2,4,6-THBA potentially interacts with CDK1 through
Arg123, Arg151, and Gly154; with CDK2 it utilizes Lys33, Gln81and Leu83; and with
CDK4, it interacts through Cys73 and His158. Phloroglucinol interacts with CDK1 using
Leu125 and Arg123; with CDK2 it utilizes Asp145 and Lys33; and with CDK4 through
Phe78 and Glu74. Interactions of 3,4,5-THBA with CDK1 occurs through Asp146; through
Lys33 for CDK2; and with CDK4 utilizing Glu74, Cys73 and Cys68. Interactions of 2,4,6THBA and phloroglucinol with CDK1 appear to be occurring in a pocket other than the
active site; in contrast 3,4,5-THBA interacts with the amino acids in the active site. In
CDK2 and CDK4, all three compounds seem to interact with amino acids in the active site.
These results also suggest that 2,4,6-THBA can potentially interact with residues involved
in CDK2-ATP-interaction.
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Table 3. 1: Free energy binding values and hydrogen bond lengths for the interaction
of 2,4,6-THBA, phloroglucinol, 3,4-DHBA, 4-HBA and 3,4,5-THBA with CDK1,
CDK2 and CDK4.
S.No

1.

2

3.

Receptor

CDK1

CDK2

CDK4

Ligand

Interacting
amino
acids

Measurement
(A°)

No of
H
bonds

2,4,6-THBA

Arg123,
Gly154,
Arg151

3,4,5-THBA

Energy
value
(kCal/mol)

2.5, 2.4, 2.0

3

-6.0

Asp 146

2.1

1

-6.1

Phloroglucinol

Leu125,
Arg123

2.4, 2.6

2

-4.9

3,4-DHBA

Asp146

2.8

1

-6.3

4-HBA

-

-

0

-6.4

2,4,6-THBA

Leu83,
Gln81,
Lys33

2.2, 2.3, 2.4

3

-5.6

3,4,5-THBA

Lys33

2.5

1

-5.8

Phloroglucinol

Asp145,
Lys33

2.2,2.4

2

-5.2

3,4-DHBA

Leu83(2),
Glu81

3.2, 3.1, 2.0

3

-5.8

4-HBA

Lys33

2.9

1

-5.7

2,4,6-THBA

His158,
Cys73

21, 2.8

2

-5.8

3,4,5-THBA

Glu74,
Cys73,
Cys68

2.2, 2.8, 1.9

3

-5.8

Phloroglucinol

Phe78,
Glu74

2.1, 2.7

2

-5.0

3,4-DHBA

Cys68,
Glu75

2.5, 2.7

2

-5.7

4-HBA

His158

3.2

1

-5.7

64

Figure 3. 3: Molecular docking revealed potential interactions of different compounds
with CDKs
Space-filling model showing the orientation of the compounds and the potential
binding pockets in CDK1 (A), CDK2 (B) and CDK4 (C) for 2,4,6-THBA (upper panel),
phloroglucinol (middle panel) and 3,4,5-THBA (lower panel).
3.3.4. 2,4,6-THBA inhibits cell proliferation in cell lines expressing functional
SLC5A8
Since 2,4,6-THBA effectively inhibited CDK activity in vitro, the possibility that
it could inhibit cell proliferation of human CRC cells was explored. Surprisingly, when
HCT-116 cells were exposed to 2,4,6-THBA (125- 1000 μM) for 72 h, no decline in cell
number was observed (Fig. 3.4). Additionally, the levels of cell cycle inhibitory proteins
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p21Cip1 and p27Kip1 also remained unaltered, and similar results were obtained in HT-29
and Caco-2 cell lines (data not shown). This prompted us to speculate that the
unresponsiveness of these cells may be due to the lack of endogenous functional
transporters for 2,4,6-THBA. We reasoned that 2,4,6-THBA being a monocarboxylic acid
may be transported through the MCT SLC5A8 [180], which is expressed in the GI and
proximal tubule for the transport of monocarboxylic acids [181, 182]. Interestingly, in
various cancers this protein is either inactivated through mutations (F251V) [182] or its
expression is suppressed through promoter methylation[183]; this possibly explains the
lack of an inhibitory effect of 2,4,6-THBA in CRC cell lines. Since a CRC cell line
expressing a functional SLC5A8 was unavailable, we sought to determine the effect of
2,4,6-THBA on a breast cancer cell line (MDA-MB-231) previously characterized and
reported to express this protein under the control of the tet-promoter (SLC5A8-pLVX)
[184]. In contrast, parental MDA-MB-231 cells have been reported to express low levels
of SLC5A8 [185].
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Figure 3. 4: Effect of 2,4,6-THBA on HCT-116 cell proliferation
Cells were treated with 2,4,6-THBA for 72h. Floating cells were collected, the
adherent cells were washed, trypsinized and pooled with the floating cells and counted.
To investigate if the effect of 2,4,6-THBA required SLC5A8 transporter function,
MDA-MB-231 and SLC5A8-pLVX cells were treated for 72h at different concentrations
from 125µM to 1000µM. Cells were counted for the inhibition of proliferation or analyzed
for the induction of various cell cycle regulatory proteins namely p21Cip1, p27Kip1, CDK1,
CDK2, CDK4, cyclin A2, cyclin B1 and cyclin D1. Figure 3.5A shows that no significant
inhibition of cell proliferation was observed in MDA-MB-231 cells at concentrations from
125-750μM; however, a reduction was observed at 1000μM. Consistent with this, 2,4,6THBA upregulated p21Cip1 and p27Kip1 protein levels at 1000μM (data not shown). In
contrast, in SLC5A8-pLVX cells, there was a clear decrease in cell density and number at
all concentrations tested, indicative of an inhibitory effect on cell proliferation (Fig. 3.5B
and C). The decreased cell number correlated with increased levels of p21Cip1 and p27Kip1
(Fig. 3.5D). In these lysates, protein levels of CDK1, CDK4, cyclin A2 and cyclin D1
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remained unaltered while levels of CDK2 and cyclin B1 were reduced at higher
concentrations (≥750μM; Fig. 3.6). Further examination of mRNA levels revealed an
increase of p21Cip1 at all concentrations whereas p27Kip1 levels were upregulated beginning
at 500µM (Fig. 3.5E and F), suggesting that 2,4,6-THBA is an effective anti-proliferative
agent. Collectively, these results indicate that SLC5A8 is a likely transporter for 2,4,6THBA, and that its uptake contributes to the observed increase in the levels of p21Cip1 and
p27Kip1, leading to inhibition of cell proliferation.

Figure 3. 5: Effect of 2,4,6-THBA on MDA-MB-231 and SLC5A8-pLVX cells
A, Graphic representation of the lack of an effect of 2,4,6-THBA on MDA-MB231 cells. B, Microscopy images showing the effect of 2,4,6-THBA in SLC5A8-pLVX
cells. C, Graphic representation showing the progressive decrease in cell number upon
treatment with 2,4,6-THBA in SLC5A8-pLVX cells. D, Western Blot analysis showing the
increase in p21Cip1 and p27Kip1 protein levels in SLC5A8-pLVX cells in response to 2,4,6THBA. E and F, qPCR analysis showing fold-increase in p21Cip1 and p27Kip1 mRNA levels
respectively in SLC5A8-pLVX cells in response to 2,4,6-THBA.
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Figure 3. 6: Western Blot analysis showing the levels of various CDKs and cyclins in
SLC5A8-pLVX cells in response to 2,4,6-THBA
3.3.5 2,4,6-THBA is taken up by cells expressing functional SLC5A8
In independent experiments, using HPLC, cellular uptake of 2,4,6-THBA by
SLC5A8-pLVX cells, MDA-MB-231 and HCT-116 cells was investigated to further
confirm that SLC5A8 is a transporter for 2,4,6-THBA. Figure 3.7A demonstrates the dosedependent uptake of 2,4,6-THBA by various cancer cell-lines. In SLC5A8-pLVX cells,
uptake was observed at 125µM and increased linearly up to 1000µM. As anticipated,
reduced uptake was observed in the parental MDA-MB-231 cells with lower SLC5A8
expression (Fig. 3.8). Importantly, in HCT-116 cells, there was no uptake of 2,4,6-THBA
despite the detection of SLC5A8 in the cell lysate (Fig. 3.8), which may be due to the
presence of a dysfunctional transporter as previously reported [185]; this is also consistent
with the lack of inhibition of proliferation in these cells (Fig. 3.7D). Together, these results
implicate SLC5A8 in the transport of 2,4,6-THBA.
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Figure 3. 7: Uptake studies of 2,4,6-THBA and its effects on colony formation in
different cell lines
A, HPLC analysis showing uptake of 2,4,6-THBA after 72h in SLC5A8-pLVX, MDAMB-231 and HCT-116 cells. B, C and D, effect of 2,4,6-THBA (14-21 days) on colony
formation in SLC5A8-pLVX, MDA-MB-231 and HCT-116 cells respectively.
Quantification of the data is shown beside the crystal violet stained image of the colonies.
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Figure 3. 8: Western Blot demonstrating the expression levels of SLC5A8 protein in
HCT-116, HT-29, MDA-MB-231 and SLC5A8-pLVX cell lines
Despite the expression of SLC5A8 in HCT-116 cells, uptake of 2,4,6-THBA was
not observed (Fig. 3.7A). In contrast, uptake was observed in SLC5A8-pLVX cells
expressing the functional transporter. Consistent with the low expression of SLC5A8 in
MDA-MB-231cells, low levels of 2,4,6-THBA was observed in these cells.
3.3.6. Clonogenic assay
Clonogenic assay was performed to demonstrate the effectiveness of 2,4,6-THBA
against colony formation in SLC5A8-pLVX, MDA-MB-231, HCT-116 and HT-29 cells.
Figure 3.7B demonstrates that in SLC5A8-pLVX cells, 2,4,6-THBA dose dependently
decreased the colony formation beginning at 125µM with a 50% reduction observed around
400µM. In addition to the decrease in the number of colonies, 2,4,6-THBA caused a
reduction in the size of the colonies. In the MDA-MB-231 cells, 2,4,6-THBA also reduced
the number of colonies after 250μM with 50% reduction observed at about 446μM (Fig.
3.7C). In contrast, the colony formation in HCT-116 (Fig. 3.7D) and HT-29 cells (Fig.
3.9A) remained unaffected at all concentrations. This further demonstrates that SLC5A8 is
a transporter for 2,4,6-THBA and its uptake leads to inhibition of cell proliferation.
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Figure 3. 9: Effect of different HBAs on colony formation in HT-29 cells
Figure shows the effect of 2,4,6-THBA (A), 3,4,5-THBA (B), 3,4-DHBA (C) and
4-HBA (D) on colony formation in HT-29 cells.
3.3.7 Cell cycle analysis and apoptosis assay
We next determined the effect of 2,4,6-THBA on cell cycle arrest and apoptosis in
SLC5A8-pLVX cells. Figure 3.10A demonstrates that no significant shift nor accumulation
of a specific phase was observed in different stages of the cell cycle under treated
conditions as compared to the untreated control. Interestingly, there was also no change in
the number of cells undergoing apoptosis following 2,4,6-THBA treatment (Fig. 3.10B).
These results when combined with the cell count data obtained in Fig. 3.5C suggests that
2,4,6-THBA is likely to slow down the rate of proliferation without causing an
accumulation at any specific stage of the cell cycle, implying that the inhibition may be
equal across all phases of the cell cycle. This is further supported by the earlier observation
in Fig. 3.1 that 2,4,6-THBA is an effective inhibitor of CDKs 1, 2 and 4. Lack of apoptosis
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observed also indicates that 2,4,6-THBA is likely to be a cytostatic agent rather than a cytotoxic
agent at the concentrations tested.

Figure 3. 10: Cell cycle and apoptosis assays
Graphic representation of A, the cell cycle analysis and B, apoptosis assay
following treatment with 2,4,6-THBA in SLC5A8-pLVX cells. The percentage of cells in
each stage was determined through flow cytometry.
3.3.8. Effect of other flavonoid metabolites (4-HBA; 3,4-DHBA; and 3,4,5-THBA)
on clonal formation
Next, the effect of metabolites generated from the flavonoid B-ring namely 4-HBA,
3,4-DHBA and 3,4,5-THBA on colony formation was investigated for comparison with
2,4,6-THBA. The data in Fig. 3.2 showed that 3,4,5-THBA did not inhibit CDK activity,
and our previous observations indicated that 3,4-DHBA is also incapable of inhibiting
CDK1 [166]. Despite the lack of CDK inhibition by these compounds, the possibility that
they may exhibit their known anti-proliferative activity [144, 162, 164, 165] following
uptake through SLC5A8 was considered. Consistent with previous reports in other cell
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lines, 3,4-DHBA and 3,4,5-THBA efficiently inhibited clonal formation in SLC5A8pLVX, MDA-MB-231, and HCT-116 cells (Figs. 3.11 and 3.12). Inhibition of cell
proliferation with 3,4-DHBA was observed beginning at a concentration of 15.62μM for
SLC5A8-pLVX, 7.3μM for MDA-MB-231 and 125μM for HCT-116 cells. Inhibition with
3,4,5-THBA was observed starting at 7.3μM in all cell-lines. The lack of CDK-inhibition
by 3,4-DHBA [166] and 3,4,5-THBA (Fig. 3.2) and the results obtained in clonogenic
assay clearly indicated that their mechanism of action is CDK-independent. Interestingly,
4-HBA failed to inhibit clonal formation at all concentrations tested (Figs. 3.9 and 3.13)
which suggests that the flavonoid metabolites are highly selective in their actions.
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Figure 3. 11: Colony formation assay following treatment with 3,4-DHBA
Effect of different concentrations of 3,4-DHBA on colony formation in SLC5A8pLVX (A), MDA-MB-231 (B), and HCT-116 (C) cells.
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Figure 3. 12: Colony formation assay following treatment with 3,4,5-THBA
Effect of different concentrations of 3,4,5-THBA on colony formation in
SLC5A8-PLVX (A), MDA-MB-231 (B), and HCT-116 (C) cells.
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Figure 3. 13: Colony formation assay following treatment with 4-HBA
Effect of different concentrations of 4-HBA on colony formation in SLC5A8pLVX (A), MDA-MB-231 (B), and HCT-116 (C) cells.
The ability of 3,4-DHBA and 3,4,5-THBA to inhibit proliferation in HCT-116 cells
(Figs. 3.11 and 3.12) was surprising as in these cells the structurally related 2,4,6-THBA
failed to inhibit cell proliferation. These contrasting results prompted the study of their
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uptake in SLC5A8-pLVX, MDA-MB-231 and HCT-116 cells. The data obtained from
HPLC analysis showed that 3,4-DHBA and 3,4,5-THBA were not taken up whereas
cellular uptake of 4-HBA was consistently observed in all three cell lines tested (Fig. 3.14).
Inhibition of cell proliferation by 3,4-DHBA and 3,4,5-THBA in all three cell lines without
their cellular uptake suggests that the biological targets for these compounds are
extracellular. The uptake of 4-HBA in all cell lines might be mediated either through an
alternative transporter or it passively diffuses across the cell membrane.

Figure 3. 14: HPLC analysis showing the cellular uptake of different HBAs
HPLC analysis showing the cellular uptake in SLC5A8-pLVX, MDA-MB-231 and
HCT-116 cells following incubation with 3,4-DHBA (A), 3,4,5-THBA (B) and 4-HBA (C)
in the cytosol.
3.4 Discussion
In this chapter, we report several novel observations including a mechanism by which
flavonoid metabolites known to be generated in the GI tract may exert their anti-cancer
effects against CRC through CDK-dependent and -independent pathways. This study
investigated 2,4,6-THBA generated from flavonoid A-ring and 4-HBA, 3,4-DHBA and
3,4,5-THBA from the flavonoid B-ring (Fig. 1.6) for their potential to inhibit cancer cell
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growth. Our results demonstrated that the inhibitory effect of 2,4,6-THBA on purified
CDKs in vitro was dose dependent with IC50 observed between 250-600µM, while
molecular docking studies revealed the key amino acid interactions. We also identified
SLC5A8 as a transporter for 2,4,6-THBA, and using SLC5A8-pLVX cells, we
demonstrated that its cellular uptake for 72h was sufficient to cause induction of p21Cip1
and p27Kip1, leading to inhibition of cell proliferation. Although endogenous SLC5A8 was
detected in HCT-116 cells, they were insensitive to 2,4,6-THBA treatment. Additionally,
using clonogenic assays, we showed that 2,4,6-THBA was highly effective in inhibiting
clonal formation in the cell lines expressing functional SLC5A8. The IC50 of clonal
inhibition corresponded to the IC50 of CDK inhibition, suggesting that 2,4,6-THBA may
mediate its effect through a CDK-dependent pathway. We believe the inhibition of
proliferation can occur through at least two different mechanisms – one by direct binding
of 2,4,6-THBA to CDKs leading to their inhibition and the other through upregulation of
CDK inhibitory proteins p21Cip1 and p27Kip1. Although 3,4-DHBA and 3,4,5-THBA were
incapable of inhibiting CDKs, they efficiently inhibited cell proliferation in all cell lines
tested including HCT-116 and HT-29 (Figs. 3.9, 3.11 and 3.12). This suggests that the
mechanism of inhibition by 3,4-DHBA and 3,4,5-THBA is both an SLC5A8- and CDKindependent phenomenon. Not all metabolites exhibited anti-proliferative effects as 4HBA although taken up by all cell lines tested was ineffective in inhibiting cell
proliferation which suggests that the metabolites are selective in their actions. Our results,
for the first time demonstrate a role for flavonoid metabolites in the inhibition of cancer
cell growth occurring through both CDK-dependent and -independent mechanisms, and
also establishes a functional role for SLC5A8 in the transport of 2,4,6-THBA.
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Molecular docking studies indicated that 2,4,6-THBA binds to CDKs 1, 2 and 4 at
specific sites within these enzymes. The CDK structure is highly conserved among the
different family members with a bi-lobe fold that harbors a conserved ATP-binding domain
[186, 187]. The interactions of 2,4,6-THBA with CDKs 2 and 4 at the ATP-binding site
may explain the enhanced inhibition of enzyme activity in comparison to the lesser
inhibition of CDK1 by 2,4,6-THBA which interacts at an allosteric site. Interestingly, the
structurally related compound 3,4,5-THBA failed to inhibit CDK activity although docking
studies provided evidence of its binding to all CDKs (Table 3.1). This suggests that the
presence of hydroxyl groups at specific positions on the benzene ring in these compounds
confers the ability to bind and cause enzyme inhibition. The –COOH group seems to be
important in increasing the potency of this inhibition as phloroglucinol which lacks the –
COOH group was only marginally effective in inhibiting CDK1 and CDK2. Therefore, we
suggest that both the presence of –COOH and the position of the -OH groups are important
for efficient CDK inhibition. Further studies involving kinetics of inhibition are required
to fully understand the nature of these interactions and its implications towards inhibition
of enzyme activity.
Detection of 2,4,6-THBA in SLC5A8-pLVX cells through HPLC suggests that
SLC5A8 is a natural transporter for this monocarboxylic acid. The attributed physiological
functions of SLC5A8 includes transport of short chain fatty acids (SCFAs), salicylates,
propionate, butyrate, lactate, pyruvate, and benzoates to name a few [182]. Numerous
studies have shown that SLC5A8 is likely to be a tumor suppressor protein[183, 184] and
the mechanism is predicted to involve inhibition of histone deacetylases (HDACs) through
the uptake of SCFAs by these transporters [182, 185]. It is a sodium-coupled MCT and is
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expressed in the apical membrane of the colonic and intestinal epithelium [181]. It is
silenced in many cancers including colon, thyroid, kidney, stomach, brain, breast, pancreas
and prostate. Studies suggest that silencing of SLC5A8 contributes to tumorigenesis [188].
We speculated that the lack of response observed following 2,4,6-THBA treatment of
HCT-116 and other CRC cell lines is due to the absence of a wild-type functional SLC5A8.
In support of this view, no cellular uptake of 2,4,6-THBA was observed in these cells.
Importantly, in SLC5A8-pLVX cells expressing the functional SLC5A8, 2,4,6-THBA not
only induced p21Cip1 and p27Kip1 RNA and protein expression, but also reduced cell
proliferation. Our demonstration that 2,4,6-THBA inhibits cell growth in cancer cells
expressing functional SLC5A8 suggests that such a phenomenon may indeed exist in vivo
and may contribute to its anti-cancer effects against CRC.
The mechanism by which 2,4,6-THBA inhibits CDK activity requires additional
investigations. Unlike the conventional drugs Palbociclib and Ribociclib that target
CDK4/6 and cause G0/G1 cell cycle arrest [189], 2,4,6-THBA appears to target CDKs 1,
2, and 4. The lack of inhibition at any particular stage of the cell-cycle observed in our
study (Fig. 3.10A) may be attributed to the effect of 2,4,6-THBA on multiple CDKs (Fig.
3.1A-C), leading to a decrease in the overall growth rate without causing accumulation of
cells at any given stage. Exposure of SLC5A8-pLVX cells to 2,4,6-THBA at
concentrations from 125µM-1000µM slowed the proliferation (Fig. 3.5C) without causing
significant apoptosis (Fig. 3.10B) suggesting that it is more likely to be a cytostatic rather
than a cytotoxic agent.
The exposure of SLC5A8-pLVX cells as well as MDA-MB-231 cells to 2,4,6-THBA
for 14-21 days resulted in a decrease in colony formation. The ability of 2,4,6-THBA to
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inhibit cell proliferation in MDA-MB-231 cells was surprising considering the low
expression levels of SLC5A8 and the fact that acute treatment (72h) with 2,4,6-THBA did
not cause any significant decrease in cell proliferation. This discrepancy between acute and
chronic treatment in MDA-MB-231 cells can be explained by the limited uptake of 2,4,6THBA during acute exposure, whereas chronic exposure of these cells to 2,4,6-THBA
could result in significant accumulation sufficient to cause inhibition of cell proliferation.
This was consistent with the HPLC data that showed lower uptake of 2,4,6-THBA in
MDA-MB-231 cells when compared to SLC5A8-pLVX cells (Fig. 3.7A). Consistent with
the previously reported lack of functional SLC5A8 in HCT-116 cells [185], 2,4,6-THBA
had no effect on the colony formation (Fig. 3.7D), and HPLC also showed no uptake of
2,4,6-THBA in these cells (Fig. 3.7A). These results suggest that the transporter activity of
SLC5A8 is required for 2,4,6-THBA-mediated inhibition of cell proliferation.
Tumor progression involves distinct stages – initiation, promotion, progression and
metastasis. Of these stages, it is suggested that chemo-preventive agents preferentially act
within the initiation and promotion stages to reverse the process of carcinogenesis [190].
They are further classified into blocking agents and suppressing agents depending on their
ability to prevent carcinogenesis and suppress neoplastic cell growth respectively [191].
Based on the properties reported for phenolic compounds [95, 192] and the results
presented in this study, we propose that 2,4,6-THBA can act as both – a blocking and a
suppressing agent. Since it is a phenolic compound with multiple hydroxyl groups, it can
act as a blocking agent and exert its effect through its antioxidant properties [96]. It can
also be viewed as a suppressing agent through its direct inhibitory effect on CDKs 1, 2 and
4 leading to reduced rate of cell proliferation. Its antioxidant and anti-proliferative actions
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could collectively contribute to cancer prevention by slowing down the rate of cell
proliferation and providing an opportunity to repair the DNA damage or for immune
surveillance by Natural Killer- and cytotoxic T-cells for cancer cell destruction [193, 194].
Although 3,4-DHBA and 3,4,5-THBA failed to inhibit CDK activity in vitro, their
ability to inhibit colony formation in all cell lines tested irrespective of the SLC5A8
expression is also an important observation. It suggests that these compounds exert their
anti-proliferative effect through an SLC5A8- and CDK-independent mechanism. These
flavonoid metabolites have previously been shown to inhibit cancer cell growth through
multiple signaling pathways [144, 162]; however, no direct primary target(s) have been
identified. It appears that depending upon the cell line tested, 3,4-DHBA and 3,4,5-THBA
can inhibit colony formation within a range of 7.3–250 μM and 7.3-31.25 μM respectively.
These concentrations are significantly lower compared to those of 2,4,6-THBA. The lack
of detection of these compounds in HPLC studies suggests that they are not taken up by
the cells, and hence we suggest that their primary target is likely to be extracellular.
The discovery of the flavonoid metabolite 2,4,6-THBA as an inhibitor of CDKs and
the demonstration of its ability to inhibit cell proliferation is a significant finding. Although
the IC50 of 2,4,6-THBA and other compounds tested in this study are in micromolar
concentrations, it could be argued that it is physiologically relevant in view of their
abundance in the diet [141, 145]. CDKs and other potential cellular targets probably have
evolved to be less sensitive to these compounds to avoid complete inhibition or perturbance
of cell cycle at lower concentrations. We suggest that the reported chemo-preventive
actions of flavonoids could be explained at least in part through the ability of its metabolite
2,4,6-THBA to target CDKs by direct inhibition and through upregulation of CDK
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inhibitory proteins; this would tip the balance strongly towards cell-cycle arrest, leading to
reduced cell proliferation. A model depicting how flavonoid metabolites may prevent the
occurrences of CRC is shown in Fig. 3.15. Since the metabolites are also generated through
microbial degradation, it highlights the importance of GI microflora in the prevention of
CRC. Effective cancer prevention may therefore require both the chemo-preventive agents
and the responsible microbial partners for their degradation. Identification of the microbial
species contributing to this process as well as the mechanism of action of the metabolites
on GI tissue is an important area for future study.
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Figure 3. 15: A model depicting how flavonoid metabolites may exert its chemopreventive effects on colonic tissue to protect against CRC
We suggest that 2,4,6-THBA generated by auto-degradation of flavonoids or those
through the action of microflora is taken up by the colonic epithelial cells through SLC5A8.
Since SLC5A8 is expressed only in the apical surface (and not in the basolateral surface)
[182], 2,4,6-THBA may accumulate to pharmacologically relevant concentrations within
cells, sufficient to inhibit CDKs. This would lead to a reduced rate of cell proliferation
through 2 distinct mechanisms – one by direct inhibition of CDKs by 2,4,6-THBA and the
other through the upregulation of p21Cip1 and p27Kip1, possibly through an indirect pathway.
The reduced rate of proliferation will provide an opportunity for DNA repair to occur or
destruction of cancer cells through immune surveillance. The metabolites such as 3,4DHBA and 3,4,5-THBA that are generated from flavonoids may also contribute to
chemoprevention by targeting extracellular proteins.

In this chapter, using a variety of biochemical, molecular biology and computational
approaches, we report that the flavonoid metabolite 2,4,6-THBA inhibits CDK enzyme
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activity and exhibits potent anti-proliferative effects. We showed that cellular uptake of
2,4,6-THBA required the expression of SLC5A8, an MCT. Investigations were also carried
out to determine the effectiveness of three other metabolites– 4-HBA, 3,4-DHBA and
3,4,5-THBA. Of these only 3,4-DHBA and 3,4,5-THBA inhibited cancer cell proliferation
and this was independent of both SLC5A8 transport and CDK inhibition. These findings
for the first time, suggests that the flavonoid metabolite 2,4,6-THBA along with 3,4-DHBA
and 3,4,5-THBA may contribute to the chemo-preventive effects of flavonoids against
CRC. In addition, our studies also highlight the need of further investigations directed
towards the role(s) played by flavonoid metabolites in the prevention of cancer. Our finding
that 2,4,6-THBA is an effective inhibitor of CDKs that acts as an anti-proliferative agent
suggests that it has the potential to be developed into a novel class of CDK inhibitors.
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CHAPTER 4: ASPIRIN METABOLITES 2,3‑DHBA AND 2,5‑DHBA INHIBIT
CANCER CELL GROWTH
4.1 Abstract
Although compelling evidence exists on the ability of aspirin to treat colorectal cancer
(CRC), and numerous theories and targets have been proposed, a consensus has not been
reached regarding its mechanism of action. In this regard, a relatively unexplored area is
the role played by aspirin metabolites 2,3‑dihydroxybenzoic acid (2,3‑DHBA) and
2,5‑dihydroxybenzoic acid (2,5‑DHBA) in its chemopreventive actions. In a previous
study, we demonstrated that 2,3‑DHBA and 2,5‑DHBA inhibited CDK1 enzyme activity
in vitro. The aim of the present study was to understand the effect of these metabolites on
the enzyme activity of all CDKs involved in cell cycle regulation (CDKs 1, 2, 4 and 6) as
well as their effect on clonal formation in three different cancer cell lines. Additionally, in
silico studies were performed to determine the potential sites of interactions of 2,3‑DHBA
and 2,5‑DHBA with CDKs. We demonstrated that 2,3‑DHBA and 2,5‑DHBA inhibits
CDK‑1 enzyme activity beginning at 500 μM, while CDK2 and CDK4 activity was
inhibited only at higher concentrations (>750 μM). 2,3‑DHBA inhibited CDK6 enzyme
activity from 250 μM, while 2,5‑DHBA inhibited its activity >750 μM. Colony formation
assays showed that 2,5‑DHBA was highly effective in inhibiting clonal formation in
HCT‑116 and HT‑29 CRC cell lines (250‑500 μM), and in the MDA‑MB‑231 breast cancer
cell line (~100 μM). In contrast 2,3‑DHBA was effective only in MDA‑MB‑231 cells
(~500 μM). Both aspirin and salicylic acid failed to inhibit all four CDKs and colony
formation. Based on the present results, it is suggested that 2,3‑DHBA and 2,5‑DHBA may
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contribute to the chemopreventive properties of aspirin, possibly through the inhibition of
CDKs.
4.2 Background and hypothesis
The goal of this chapter was to understand if aspirin metabolites 2,3-DHBA and 2,5DHBA can prevent cancer cell growth. Our laboratory has been focusing on determining a
role for aspirin and salicylic acid metabolites 2,3-dihydroxybenzoic acid (2,3-DHBA) and
2,5-dihydroxybenzoic acid (2,5-DHBA), known to be generated in the body by the
cytochrome P-450 (CYP450) catalyzed reactions [150], in the prevention of CRC.
Interestingly, similar dihydroxybenzoic acids have also been reported to be generated from
aspirin by the gut microflora [154]. In a previous study we demonstrated the ability of 2,3DHBA and 2,5-DHBA to inhibit CDK1 activity in vitro [166]. However, an extended study
on the effect of these metabolites on other CDKs involved in cell-cycle regulation (CDK2,
CDK4 and CDK6) as well as the demonstration of their ability to inhibit cancer cell growth
were not reported. As a dysregulated cell cycle is one of the hallmarks of cancer, it was
important to determine if 2,3-DHBA and 2,5-DHBA affected cancer cell growth by
inhibiting these CDKs to gain a comprehensive understanding of their mechanism of
action. In the present study, we investigated the effect of 2,3-DHBA and 2,5-DHBA on
CDKs 1, 2, 4 and 6 enzyme activities and determined their potential sites of interaction
within these enzymes. In addition, we also performed studies to determine the effect of
these metabolites on cancer cell proliferation.
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4.3 Results
4.3.1 Effect of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA on CDK enzyme
activity
We initiated this study by determining the dose-dependent effect of aspirin,
salicylic acid, 2,3-DHBA and 2,5-DHBA on recombinant CDKs 1, 2, 4 and 6 by measuring
the phosphorylation pattern through in vitro kinase assays. Figure 4.1 shows that CDK1
activity remained unaffected following treatment with aspirin and salicylic acid at all
concentrations tested (125 µM to 1 mM); however, 2,3-DHBA and 2,5-DHBA inhibited
CDK1 activity, confirming our previously published results [166]. In both cases, inhibition
was around 20% at 500 μM, 40% at 750 μM and 60% at 1000 μM. CDK2 activity remained
unchanged upon exposure to aspirin and salicylic acid while inhibition was observed with
2,3-DHBA and 2,5-DHBA, especially at higher concentrations (>750 μM; Fig. 4.2).
Similar to CDK1 and CDK2, aspirin and salicylic acid both failed to inhibit CDK4 and
CDK6 enzyme activity (Figs. 4.3 and 4.4). 2,3-DHBA and 2,5-DHBA inhibited CDK4
activity at 1000 µM. 2,3-DHBA was able to inhibit CDK6 enzyme activity beginning at
250 µM, while 2,5-DHBA inhibited CDK6 enzyme activity at concentrations >750 μM.
These results show 2,3-DHBA and 2,5-DHBA were able to inhibit CDKs 1, 2, 4, and 6
activities to different degrees. It is also important to note that the inhibition observed with
CDK1 by 2,3-DHBA and 2,5-DHBA, and CDK-6 by 2,3-DHBA was significantly greater
compared to inhibition of other CDKs by these compounds.
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Figure 4. 1: Effect of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA on CDK1
enzyme activity
A, B, C and D show the effect of different concentrations of aspirin, salicylic acid,
2,3-DHBA and 2,5-DHBA respectively on CDK1 enzyme activity. H1 histones were used
as the substrate for CDK1. Upper panel shows phosphorylation of H1 Histones in the
presence of different concentrations of each compound. The middle panel shows the
coomassie blue stained proteins. Lower panel represents the quantification of the bands in
upper panel. The concentration of the drugs used are indicated in micromolar (μM).
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Figure 4. 2: Effect of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA on CDK2
enzyme activity
A, B, C and D show the effect of different concentrations of aspirin, salicylic acid,
2,3-DHBA and 2,5-DHBA respectively on CDK2 enzyme activity. H1 histones were used
as the substrate for CDK2. Upper panel shows phosphorylation of H1 Histones in the
presence of different concentrations of each compound. The middle panel shows the
coomassie blue stained proteins. Lower panel represents the quantification of the bands in
upper panel. The concentration of the drugs used are indicated in micromolar (μM).
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Figure 4. 3: Effect of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA on CDK4
enzyme activity
A, B, C and D show the effect of different concentrations of aspirin, salicylic acid,
2,3-DHBA and 2,5-DHBA respectively on CDK4 enzyme activity. Retinoblastoma protein
was used as the substrate for CDK4. Upper panel shows phosphorylation of retinoblastoma
protein in the presence of different concentrations of each compound. The middle panel
shows the coomassie blue stained proteins. Lower panel represents the quantification of
the bands in upper panel. The concentration of the drugs used are indicated as micromolar
(μM).
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Figure 4. 4: Effect of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA on CDK6
enzyme activity
A, B, C and D show the effect of different concentrations of aspirin, salicylic acid,
2,3-DHBA and 2,5-DHBA respectively on CDK6 enzyme activity. Retinoblastoma protein
was used as the substrate for CDK6. Upper panel shows phosphorylation of retinoblastoma
protein in the presence of different concentrations of each compound. The middle panel
shows the coomassie blue stained proteins. Lower panel represents the quantification of
the bands in upper panel. The concentration of the drugs used are indicated as micromolar
(μM).
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4.3.2 Docking studies reveal binding pockets for aspirin, salicylic, 2,3-DHBA, and
2,5-DHBA
AutoDock Vina was used to predict the potential interactions of aspirin, salicylic
acid, 2,3-DHBA and 2,5-DHBA with CDKs 1, 2, 4 and 6. The binding free energy and
hydrogen bond lengths were also determined. The results of the docking studies are shown
in Table 4.1 and Figure 4.5 (line model). All the compounds tested interacted with CDKs
and utilized amino acids either residing in the active site or at alternate binding pockets.
Docking studies revealed that 2,3-DHBA potentially interacts with CDK1 through
Asp146; with CDK2 it utilizes Lys33, and Asp145; with CDK4, it interacts through Cys68
and His158 and with CDK6 it binds to Asp134, Tyr292, Ala291 and Thr198. 2,5-DHBA
interacts with CDK1 using Asp146; with CDK2 it utilizes Asp145 and Lys33; with CDK4
through His158; and with CDK6 it uses Lys43, Tyr24 and Gly25. Salicylic acid and aspirin
also interacted with all 4 CDKs (Table 4.1), although CDK inhibition was not observed in
vitro (Figs. 4.1-4.4). Notable interactions are that between the drug molecules and Asp146
of CDK1, as this amino acid is involved in CDK-ATP interactions [179]. Although
salicylic acid interacted with CDK1 through Asp146 and Lys33 and CDK2 through
Asp145 and Lys33, it is not clear at this stage why it failed to cause inhibition of the
enzyme activity. This may be due to the formation of an intramolecular hydrogen bond
between its carboxyl and hydroxyl groups which may hinder its interactions with CDKs.
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Figure 4. 5: Line model showing the interactions of aspirin, salicylic acid, 2,3-DHBA
and 2,5-DHBA with CDK1, CDK2, CDK4 and CDK6
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Table 4. 1: Free energy binding values and hydrogen bond lengths for the interaction
of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA with CDK1, CDK2, CDK4 and
CDK6
S.
No

1

2

3.

4.

Receptor

CDK1

CDK2

CDK4

CDK6

Ligand

Interacting
amino acids

Measurement
(A°)

No of
H
bonds

Energy
value
(kCal/mol)

Aspirin

Asn133, Tyr15

2.5, 3.0

2

-6.6

Salicylic
acid

Asp146, Lys33

2.8, 3.5

2

-6.4

2,3-DHBA

Asp146

2.9

1

-5.9

2,5-DHBA

Asp146

2.9

1

-5.9

Aspirin

Asp145,
Glu51,
Lys33(2)

3.2, 2.6, 3.1,
3.0

4

-6.2

Salicylic
acid

Asp145,
Lys33(2)

3.3, 3.0, 3.3

3

-5.7

2,3-DHBA

Lys33, Asp145

3.2, 3.2

2

-5.6

2,5-DHBA

Asp145,
Lys33(2)

3.2, 2.9, 2.9

3

-5.9

Aspirin

His158,
Gln183

2.9, 2.0

2

-5.8

Salicylic
acid

His158,
Gln183

2.8, 1.8

2

-5.4

2,3-DHBA

His158, Cys68

3.1, 2.2

2

-5.8

2,5-DHBA

His158

3.1

1

-5.4

Aspirin

Lys43

2.9

1

-5.4

Salicylic
acid

Gly165,
Leu166,
Arg144

3.1, 2.8, 3.0

3

-5.1

2,3-DHBA

Asp134,
Tyr292,
Ala291(2),
Thr198

2.0, 3.0, 3.2,
2.9, 2.9

5

-5.4

2,5-DHBA

Lys43(2),
Tyr24, Gly25

3.2, 3.2, 3.2,
3.2

4

-5.3
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4.3.3 Effect of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA on colony formation
Clonogenic assay was performed to determine the effectiveness of aspirin, salicylic
acid, 2,3-DHBA and 2,5-DHBA on colony formation in HCT-116 and HT-29 colon cancer
cells as well as MDA-MB-231 breast cancer cells. HCT-116 and HT-29 cells were chosen
to study the effect of these compounds as these cell line have been extensively used in
studies pertaining to aspirin’s biological effects [195, 196]; MDA-MB-231 cells were
chosen to determine if this effect was mimicked in another cancer cell line. We observed
that aspirin and salicylic acid both failed to inhibit colony formation in HCT-116 (Fig. 4.6A
and B), HT-29 (Fig. 4.7A and B) and MDA-MB-231 cells (Fig. 4.8A and B). 2,3-DHBA
was effective in MDA-MB-231 cells at higher concentrations (>500 μM) (Fig. 4.8C), while
it was ineffective in HCT-116 (Fig. 4.6C) and HT-29 cells (Fig. 4.7C). Interestingly, 2,5DHBA exhibited a dose dependent effect on colony formation in all cell lines examined
(Figs. 4.6D, 4.7D, 4.8D). In HCT-116 cells, decreased colony formation was observed with
2,5-DHBA at concentrations >250 μM, in HT-29 cells at concentrations >200 μM, and in
MDA-MB-231 cells, beginning at 50 μM. In contrast, two other salicylic acid derivatives
2,4-DHBA and 2,6-DHBA were unable to inhibit colony formation in MDA-MB-231 cells
(Fig. 4.9). These results clearly show that although the sensitivity varies among different
cell lines, both 2,3-DHBA and 2,5-DHBA exhibit the ability to inhibit cancer cell
proliferation in contrast to aspirin and salicylic acid.
Interestingly, 2,3-DHBA and 2,5-DHBA were ineffective in inhibiting cell
proliferation in MDA-MB-231 cells over a range of concentrations (125-1000 μM) for 2448h (Fig. 4.10). We suggest that the lack of inhibition in acute treatment observed may be
related to the poor uptake of these compounds.

97

Figure 4. 6: Effect of aspirin, salicylic acid and its metabolites on HCT-116 colony
formation
Effect of aspirin (A), salicylic acid (B), 2,3-DHBA (C) and 2,5-DHBA (D) on
colony formation in HCT-116 cells. Quantification of the data is shown beside the crystal
violet stained image of the colonies. The graph is represented as mean ± standard deviation.
The concentration of the drugs used are indicated as micromolar (μM).
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Figure 4. 7: Effect of aspirin, salicylic acid, 2,3-DHBA and 2,5-DHBA on HT-29
colony formation
Effect of aspirin (A), salicylic acid (B), 2,3-DHBA (C) and 2,5-DHBA (D) on
colony formation in HT-29 cells. Quantification of the data is shown beside the crystal
violet stained image of the colonies. The graph is represented as mean ± standard deviation.
The concentration of the drugs used are indicated as micromolar (μM).
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Figure 4. 8: Effect of aspirin, salicylic acid and its metabolites on MDA-MB-231
colony formation
Effect of aspirin (A), salicylic acid (B), 2,3-DHBA (C) and 2,5-DHBA (D) on
colony formation in MDA-MB-231 cells. Quantification of the data is shown beside the
crystal violet stained image of the colonies. The graph is represented as mean ± standard
deviation. The concentration of the drugs used are indicated as micromolar (μM).
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Figure 4. 9: Effect of 2,4-DHBA and 2,6-DHBA on colony formation in MDA-MB-231
cells
Quantification of the data is shown beside the crystal violet stained image of the
colonies. The concentration of the drugs used are indicated as micromolar (μM).

101

Figure 4. 10: Effect of 2,3-DHBA (A) and 2,5-DHBA (B) on cell number in MDA-MB231 cells
Cells were seeded at a density of 250,000 cells/ 100mm plate overnight and treated
with the indicated compounds for 48h. Cells were then trypsinized and counted using an
automated cell counter. More than 96% of the cells were viable. The concentration of the
drugs used are indicated as micromolar (μM).

4.4 Discussion
Despite the growing evidence for aspirin’s ability to decrease CRC, the mechanisms
involved remain poorly defined. Numerous hypotheses commencing from the COX
inhibition in platelets [65, 98, 197] to increased expression of DNA repair proteins,
transcription factors and interconnected signaling pathways have been proposed [198-201];
however, a consensus has not been reached regarding the target/pathway(s) primarily
responsible for its anti-cancer effects [202]. In this research paper, we tested the hypothesis
that aspirin metabolites 2,3-DHBA and 2,5-DHBA may mediate its chemopreventive
actions by inhibiting CDKs and affecting cell growth. We provide evidence that 2,3-DHBA
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and 2,5-DHBA inhibit CDKs involved in cell-cycle regulation (CDKs 1, 2, 4 and 6),
although to different degrees. Inhibition of CDK1 by 2,3-DHBA and 2,5-DHBA was
observed at 500 μM, and CDK-6 by 2,3-DHBA was observed starting at 250 µM, however,
inhibition of other CDKs by these compounds required much higher concentrations (750
µM), suggesting that CDK1 and CDK6 are better targets for 2,3-DHBA and/or 2,5-DHBA.
In contrast, aspirin and salicylic acid both failed to inhibit CDK-1, 2, 4 and 6 enzyme
activity. Through molecular docking studies we identified potential sites of these
interactions; most of the interacting amino acids appear to be localized in the active site of
these enzymes. Importantly, we also demonstrated the ability of aspirin/salicylic acid
metabolites to inhibit clonal formation in cancer cell lines. 2,5-DHBA inhibited colony
formation in a dose-dependent manner in three different cancer cell lines (HCT-116, HT29 and MDA-MB-231). In contrast, 2,3-DHBA exhibited effective inhibition in MDAMB-231 cells alone. These results suggest that 2,3-DHBA and 2,5-DHBA may be involved
in aspirin’s chemopreventive actions. Our findings raise two important questions: 1) What
are the sources of the aspirin metabolites 2,3-DHBA and 2,5-DHBA?; 2) Are there unique
scenarios that gives an anatomical advantage to 2,3-DHBA and 2,5-DHBA to act against
CRC?
Plain aspirin (non-enteric coated) is absorbed in the stomach where the acidic
environment protects it from deacetylation and ionization, resulting in its faster absorption;
however, aspirin may also be absorbed in the upper small intestine and enter into the
hepatic portal vein [203-205]. In addition, lymphatic uptake of some aspirin and salicylic
acid has been reported [205]. We hypothesize that aspirin’s preferential effect against CRC
(over other tissues) may be related to the generation of salicylic acid that occurs both
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through hydrolysis and the action of gut esterases [206] in the intestine or colon. Intact
aspirin’s bioavailability is between 50-68% [101, 102], and it is estimated that nearly 2939% of aspirin may be hydrolyzed in the GI tract, particularly in the duodenum and ileum
[102]. Therefore, it can be argued that epithelial cells of the intestine and colon are likely
to be exposed to substantially higher concentrations of salicylic acid compared to other
tissues in the body. With enteric coated aspirin, the concentration of aspirin/salicylic acid
exposed to the GI cells may be even greater than non-enteric coated tablets as the
bioavailability of intact aspirin from enteric coated tablets is significantly lower compared
to plain aspirin due to slow release and absorption in the intestine [203, 207].
Aspirin in the systemic circulation is known to be metabolized in the liver to 2,3-DHBA
and 2,5-DHBA through the action of cytochrome P450 (CYP450s) enzymes. However, it
is unlikely that these liver generated metabolites contribute to the anti-cancer effect in
colorectal tissues due to their low concentrations in the plasma [150]. We suggest that there
are two routes through which intestinal epithelial cells may get exposed to 2,3-DHBA and
2,5-DHBA. As intestinal epithelial cells also express CYP450s similar to the isoforms
expressed in the liver involved in aspirin metabolism [208], one would expect aspirin
metabolites to be generated in these cells; however, it is not clear at this stage to what extent
these metabolites are produced within the GI cells. Since exposure of HCT-116, HT-29
and MDA-MB-231 cells to aspirin or salicylic acid (up to 1 mM) failed to inhibit clonal
formation, it is likely that the contributions of cellular CYP450s to the formation of 2,3DHBA and 2,5-DHBA is negligible, although a small amount may still be produced
through this route. We have not determined the effect of aspirin and salicylic acid on clonal
formation at concentrations greater than 1 mM, therefore we are not sure if higher

104

concentrations will have an effect on clonal formation. An alternative possibility and an
attractive hypothesis is that the significant amount of aspirin / salicylic acid left unabsorbed
(32-50%) in the lumen of the intestine and colon maybe metabolized by the intestinal
microflora to generate hydroxyl derivatives of salicylic acid, which may include both 2,3DHBA and 2,5-DHBA. Bacteria are capable of metabolizing drugs through hydroxylations
[209], and one report in 2016 showed that incubation of aspirin with human fecal
suspensions containing microbiota resulted in the degradation of aspirin to salicylic acid
and hydroxylated salicylic acids [154]. The authors also showed that in rats orally
administered with aspirin and ampicillin, the bioavailability of aspirin in the plasma was
much higher compared to rats administered with aspirin alone, suggesting that microbiota
contributes to the degradation of aspirin in the GI tract. An estimation of the salicylic acid
present in the lumen of human gut has not been made, nor has the characterization of the
hydroxyl derivatives of salicylic acid produced in the lumen been reported till date. The
absence of experimental evidence on the potential formation of 2,3-DHBA and 2,5-DHBA,
beyond what is reported in literature by Kim et al. [154], is a limitation of this study. Further
work is also required to determine how these metabolites are taken up by the normal, noncancerous epithelial cells of the intestine and colon and their effect on colony formation,
which is also a limitation of this study. Regarding the uptake mechanism, one possibility
is that 2,3-DHBA and 2,5-DHBA may be taken up by the monocarboxylate transporter
(MCT) SLC5A8 as it is implicated in the transport of other derivatives of salicylic acid
[171]. The differential sensitivity of HCT-116 and HT-29 vs. MDA-MB-231 could be
attributed to the differential expression of this transporter due to mutational/ methylationdriven inactivation of the SLC5A8 gene as explained in the previous chapter.
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We observed that 2,5-DHBA was universally effective in inhibiting colony formation
as compared to 2,3-DHBA. Significant inhibition of clonal formation was observed with
2,5-DHBA at 500 μM in HCT-116 cells, at 250 μM in HT-29 cells and at 100 μM in MDAMB-231 cells, whereas 2,3-DHBA failed to inhibit colony formation in HT-29 and HCT116 cells (125-1000 μM). However, it inhibited the colony formation at ~500 μM in MDAMB-231 cells. It appears that 2,3-DHBA and 2,5-DHBA show differential inhibitory
effects in different cancer cell lines and it is unclear whether this is due to the differences
in uptake of these compounds by the cell lines tested. Two other salicylic acid derivatives
namely 2,4-DHBA and 2,6-DHBA failed to inhibit colony formation in MDA-MB-231
cells (Fig. 4.9). This suggests that among the different salicylic acid derivatives tested, 2,5DHBA is universally effective whereas 2,3-DHBA is more selective as an anti-proliferative
agent.
In contrast to the clear inhibitory effect of 2,3-DHBA and 2,5-DHBA in clonal
formation (21 days), both compounds failed to show any appreciable inhibitory effect on
cell number when cells were treated for 24-48 hours (acute treatment) at various
concentrations (125 to 1000 µM; see Fig. 4.10). Similarly, in acute treatment experiments,
both compounds failed to show an effect on cell cycle progression as measured by flow
cytometry, and owing to the lack of an effect, we have not included this data. This
discrepancy in the results between acute and chronic treatment may be related to the time
required for uptake and accumulation of these compounds to exert an inhibitory effect. We
suggest that acute exposure for 24-48 h may result in limited uptake of the drugs resulting
in milder effects which are difficult to discern in flow cytometry analysis and cell counting,
whereas chronic exposure for 21 days may result in significant accumulation of the drugs
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sufficient to cause inhibition of cell proliferation as measured by clonal formation assays.
As we have not performed flow cytometry analysis on clonal cells following chronic
exposure, it is not clear what stages of the cell cycle are affected by these compounds, and
this is another limitation of the study.
Although the IC50 of the compounds tested in this study are in micromolar
concentrations for both CDK inhibition and clonal formation, it could be argued that it is
physiologically relevant in view of their abundance in the intestine due to the hydrolysis
of aspirin to salicylic acid in the gut [101, 102]. It is also important to note that 2,3-DHBA
and 2,5-DHBA are abundantly available in fruits and vegetables [210] and one study
demonstrated that the phenolic acid content generated from the diet in the gut can rise to
micromolar concentrations [211]. CDKs and other potential cellular targets probably have
evolved to be less sensitive to these compounds to avoid complete inhibition of cell cycle
at lower concentrations. The importance of 2,5-DHBA in cancer prevention was also
demonstrated in a recent study which showed that it is effective in inhibiting colony
formation and DNA synthesis in C6 glioma cells in vitro, and enhanced survival of Ehrlich
breast ascites carcinoma bearing mice [212]. In addition, 2,5-DHBA has been implicated
in a previous report as a potential aspirin metabolite formed through the action of tyrosinase
enzyme in melanoma cells. The study stated that p-quinone formation from 2,5-DHBA was
responsible for aspirin’s anti-melanoma effects through ROS formation [133]. Thus,
although both the studies implicate anti-cancer effects of 2,5-DHBA, the mechanisms
described are starkly different; in melanocytes it occurs through depletion of GSH and
generation of ROS leading to cell apoptosis [133], while in our study (in HT-29, HCT-116,
and MDA-MB-231 cells) it involves inhibition of CDKs leading to suppression of cancer
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cell growth. This suggest that 2,5-DHBA may contribute to anti-cancer effects through
distinct mechanisms in different cell types.
The demonstration of 2,3-DHBA and 2,5-DHBA to inhibit cancer cell growth is a
significant observation in view of aspirin’s reported ability to decrease CRC. An
unanswered question is: what is/are the target(s) for 2,3-DHBA and 2,5-DHBA in cells?
Our previously published data [166] and the present study show that 2,3-DHBA and 2,5DHBA inhibited CDK1/CDK6 activity. However, at this stage it is not known if these two
observations are related, or if the inhibition of proliferation by these compounds is due to
an alternative mechanism not involving CDKs. In this context, a previous study reported
that 2,5-DHBA can interfere with FGF function by disrupting the receptor-growth factor
signaling complex in vitro and in cell culture studies [213]. At this stage, we believe that
2,5-DHBA does not target COX-2 to mediate its chemo-preventive effect in the GI
epithelial cells as HCT-116 cells are reported to lack COX-2 expression while HT-29 cells
express inactive COX-2 [214].Since both these cell lines were inhibited by 2,5-DHBA, it
suggests that the aspirin metabolites can inhibit cancer cell proliferation through a COX-2
independent mechanism. Therefore, greater efforts need to be placed into these relatively
unexplored areas to determine how 2,3-DHBA and 2,5-DHBA exert their chemopreventive
actions. Whether microbiota generated salicylic acid metabolites becomes available for
CDK inhibition following their uptake into the GI cells is an interesting area for future
study. If proven, this will highlight the contribution of the gut microflora to aspirin’s
chemoprevention against CRC, through formation of 2,3-DHBA and 2,5-DHBA. A model
depicting how 2,3-DHBA and 2,5-DHBA generated in the GI lumen through the microbial
degradation of aspirin/salicylic acid, leading to inhibition of CDKs and cell proliferation is
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shown in Fig. 4.11. We suggest that the ability of aspirin to inhibit tumor formation in the
intestinal/colonic mucosa may be a local effect via salicylic acid metabolites generated in
the gut acting on epithelial cells and may not require absorption into the blood.

Figure 4. 11: A model depicting how aspirin metabolites may exert its chemopreventive effects on colonic tissue to protect against CRC
We hypothesize that aspirin and salicylic acid may impede events/pathways crucial
to tumor formation through its metabolites 2,3-DHBA and 2,5-DHBA. We suggest that
2,3-DHBA and 2,5-DHBA generated from salicylic acid by the action of gut microflora is
taken up by the colonic epithelial cells. The uptake of these metabolites may occur through
SLC5A8, a monocarboxylic acid transporter. Accumulation of these metabolites within the
epithelial cells may result in CDK inhibition. This may cause reduced cell proliferation,
allowing an opportunity for DNA repair and immune surveillance, thereby preventing
tumorigenesis. Alternatively, it is also possible that 2,3-DHBA and 2,5-DHBA may have
additional targets contributing to cancer prevention.
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Nearly 35 years have passed since the initial report of aspirin’s ability to decrease
incidences of CRC [97], however, debates still continue on its mode of action. Although
the platelet hypothesis is widely discussed in literature, it has its own short-comings and
appears to work indirectly through a set of sequential steps involving two COX isoforms
(COX-1 and COX-2) [65, 98, 103, 197, 215, 216]. COX-1 is the only form of COX in
platelets and is constitutively expressed in all tissues, whereas COX-2 is inducible and
expressed under inflammatory conditions. COX-2 levels are also elevated in many cancers
[204, 217-220]. The half-life of intact aspirin is about 15-20 min [149] in the systemic
circulation and this period appears to be enough to cause inhibition of COX-1 in platelets
[107]. As chronic inflammation is linked to cancer, it is suggested that aspirin may mediate
its effect through inhibition of these COX enzymes. However, aspirin is more effective in
the inhibition COX-1 (IC50 1.67 μM) than COX-2 (IC50 278 μM) [109]. Since low dose
aspirin (75-160 mg) is as effective as higher doses [64], the possibility of aspirin directly
targeting COX-2 as a potential mechanism to decrease cancer is thought to be unlikely
because lower doses administered per day is insufficient to cause COX-2 inhibition. It is
suggested that aspirin’s effects may involve sequential inhibition of COX-1 and COX-2
[65, 98, 215]. This theory states that inhibition of COX-1 in platelets leads to prevention
of platelet aggregation which subsequently prevents the release of lipid mediators (e.g.,
PGE-2; TXA2), cytokines and growth factors (e.g. PDGF) from the alpha-granules. These
events could inhibit the induction of COX-2 in regions of GI mucosal lesions, preventing
tumorigenesis.
If inhibition of COX-1 in platelets in the blood following its absorption is the primary
mechanism as proposed in the platelet hypothesis [65, 197, 215], one would expect aspirin
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to decrease the incidences of cancer to the same extent in all tissues in the body, unless one
assumes that GI mucosal tissues are more prone to lesions which leads to platelet
aggregation, creating an environment suitable for eliciting an inflammatory response. It is
intriguing that aspirin that is only present for less than 20 min. in the circulation, while
capable of preventing platelet activation and aggregation, could have such a profound
effect against CRC development. While inhibition of COX-1 in platelets may play a role
(e.g. in the inhibition of metastasis), it is likely that other pathways may play a major role
in aspirin’s cancer preventive actions.
Although the “platelet hypothesis” is an attractive theory, we suggest that alternative
mechanisms as proposed in this study involving locally generated salicylic acid metabolites
by the gut microflora from aspirin as potential contributors to chemoprevention should be
considered. As ~50% of orally administered aspirin is left unabsorbed in the GI lumen
[101, 102], one would expect the concentration of aspirin from an 81 mg tablet to be in the
range of 0.3 mM to 1.4 mM in the gut assuming that the total GI fluid volume under fed
and fasting conditions are ~750 ml and ~160 ml respectively [221]. Presence of microflora
in the GI lumen may thus be able to generate 2,3-DHBA and/or 2,5-DHBA from
aspirin/salicylic acid, sufficient to cause inhibition of cell proliferation, allowing aspirin to
act locally on colorectal tissues, thus adding merit to our hypothesis. It is likely that locally
generated metabolites will provide a more direct effect on colorectal tissues against CRC
as compared to the indirect mechanism involving sequential steps proposed in platelet
hypothesis through COX-1 and COX-2 inhibition. In vivo studies utilizing germ-free mice
should shed light on the role of aspirin/salicylic metabolites and the microflora in aspirin’s
chemo-preventive properties.
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CHAPTER 5: IDENTIFICATION OF BACTERIAL SPECIES THAT CAN
METABOLIZE QUERCETIN
5.1 Abstract
The studies presented in chapter 3 demonstrated that flavonoid metabolites inhibit
cancer cell proliferation through both CDK -dependent and -independent mechanisms.
Literature evidence suggest that the gut microbiota are capable of flavonoid
biotransformation to generate bio-active metabolites including 2,4,6-THBA, 3,4-DHBA,
3,4,5-THBA and DOPAC. In this chapter, we screened 94 human gut bacterial isolates for
their ability to biotransform the flavonoid quercetin into different metabolites. We
demonstrated that of the 94 strains screened, 6 were able to degrade quercetin including
Bacillus glycinifermentans, Flavonifractor plautii, Bacteroides eggerthi, Olsonella
scatoligenes, Eubacterium eligens, and Lactobacillus spp. Additional studies showed that
B. glycinifermentans could generate 2,4,6-THBA and 3,4-DHBA from quercetin while F.
plautii generated DOPAC. In addition to the differences in the metabolites produced, we
also demonstrated that the kinetics of quercetin degradation was different between B.
glycinifermentans and F. plautii, suggesting that the pathways of degradation are likely
different between these strains. Similar to the anti-proliferative effects of 2,4,6-THBA and
3,4-DHBA demonstrated previously, DOPAC also exhibited potent inhibitory effect
against colony formation, in vitro. Thus, as B. glycinifermentans and F. plautii generate
metabolites possessing anti-proliferative activity, we suggest these strains have the
potential to be developed into probiotics to improve human gut health.
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5.2 Background and hypothesis
In the past, clinical and epidemiological studies have largely focused on the ability of
flavanols to prevent cancer. Of these flavanols, quercetin has been extensively studied not
only for its anti-cancer effects but also for its anti-inflammatory, anti-thrombotic, antineurodegenerative, anti-infectious and immunomodulatory activities [222, 223]. Quercetin
is one of the most abundant flavonoids in the diet and can be found in many foods including
onions, apples, grapes, berries, citrus fruits, tea, cherries and broccoli. It has been estimated
that humans consume 10–100 mg of quercetin every day on average through their diet
[222]. The reported health benefits are predicted to occur through quercetin’s (a)
interaction with cellular receptors, (b) modification of signal transduction pathways, (c)
antioxidant properties, and (d) apoptosis regulation, to name a few [224-226].
Quercetin however is not freely present as an aglycone in most of these food sources.
It is usually conjugated to a sugar moiety (forming glycosides) that confers water solubility
and chemical stability to these compounds [227]. The sugar moiety attached to quercetin
is usually glucose or rhamnose, but it could also be galactose, arabinose, xylose, or other
sugars [228]. Quercetin glycosides are poorly absorbed from the intestine, and hence these
linkages are cleaved by enzymes either present in the small intestine or the colon to
facilitate absorption [141, 229]. As the enzymes produced by the human body is sometimes
incapable of cleaving the glycosidic linkages, microbial enzymes produced have been
implicated in these deconjugation reactions. For example, studies have suggested that the
hydrolysis of rutin (quercetin-3-O-rutinoside; from onions, berries etc.) to quercetin occurs
through the action of the gut microbiota [230, 231]. Studies highlighting the importance of
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the gut microflora in human health are now emerging, wherein the microbiota is considered
as a separate organ by itself [232-235].
Numerous studies have implicated the dysregulation of the microbial ecology in the
intestine to be a cause for colorectal cancers (CRC). These studies have also indicated that
diet is a major factor governing the dysbiosis wherein regular intake of fruits and
vegetables seem to favorably shift the ecology of the gut microbes to a cohort that can
prevent the occurrence of CRC [139, 236-240]. Increasing studies are also implicating a
beneficial role for the microbial metabolites in human health, especially in cancer [136,
171, 241]. Taken together, these studies are indicative of the importance of the gut
microbes and their catabolites following flavonoid degradation in influencing human
health. Hence, identifying the mechanisms involved in flavonoid catabolism, and the
various microbial enzymes involved in this process, would aid in understanding and
establishing the key contributors of the beneficial metabolites.
Studies conducted this far have identified quercetin-2,3-dioxygenase (quercetinase) as
the first enzyme in Bacillus spp. that is required for the metabolism of quercetin [242]. The
reaction catalyzed by quercetinase is shown in Fig. 5.1A. As can be seen from this reaction,
the ester product 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoate can then be
cleaved by the gut esterases to 2,4,6-THBA and 3,4-DHBA. Other studies have also
demonstrated that alternative pathways may also exist for quercetin degradation,
generating 3,4-dihydroxyphenylacetic acid (DOPAC) through biotransformation of this
flavonoid by other bacteria (Fig 5.1B)[136, 243]. The generation of DOPAC from
quercetin is predicted to occur through the involvement of phloretin hydrolase [244]. A
recent study also suggested the involvement of ene-reductases in the biotransformation of
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flavones and flavonols [245]. Apart from these enzymes, other enzymes known to be
involved in flavonoid metabolism include chalcone isomerase and enoate reductase from
Eubacterium ramulus [246], and peroxidases, dehydrogenases, demethylases and
tyrosinases from a variety of bacteria [247].

Figure 5. 1: Catabolic pathways proposed for quercetin degradation
(A) Reaction representing the microbial catabolism of quercetin to 2-(3,4dihydroxybenzoyloxy)-4,6-dihydroxybenzoate and carbon monoxide by quercetinase
found in Bacillus spp. [248] (B) Proposed mechanism of quercetin degradation to generate
DOPAC [136]

In the preceding chapters we demonstrated the ability of 2,4,6-THBA, one of the
metabolites generated from flavonoid degradation by the gut microbiota, to inhibit cancer
cell growth, possibly through inhibition of CDK enzymes [171]. This provided a basis for
the hypothesis that the human gut microbiota maybe crucial for the generation of anticancerous metabolites from flavonoids. The goal of this chapter was to identify the bacteria
capable of degrading quercetin, a flavonol, and identify the metabolites, with a focus on
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2,4,6-THBA, 3,4-DHBA and 3,4-dihydroxyphenyl acetic acid (DOPAC). Our results
identified 6 bacterial strains (from the human gut bacterial library) with flavonoid
degrading capability. Among these strains, Bacillu glycinifermentans generated 2,4,6THBA and 3,4-DHBA, while Flavonifractor plautii generated DOPAC from quercetin,
with different kinetics of degradation between the two bacterial strains. Additionally, we
demonstrated that DOPAC has potent anti-proliferative properties against cancer cells,
highlighting the importance of the contribution of bacteria in generating bio-active
metabolites for the prevention of cancers.
5.3 Results
5.3.1 Screening the human gut bacterial library for quercetin degrading strains
Ninety-one bacterial strains obtained from the human gut library and 3 standard
strains obtained from DSM, Germany were individually screened for their ability to
degrade quercetin under anaerobic conditions in 7N minimal media containing 75μg/ml
quercetin (7NQ media) as described in materials and methods. To ensure that the quercetin
peak did not coincide with any other components present in the spent media, we also grew
the cells in 7N media and analyzed the spent supernatant through HPLC. We also had a
blank 7NQ media (without any bacterial inoculation; control) to account for the autodegradation of quercetin. The results obtained from the bacterial spent media were
compared to that of the 7NQ media control and the results are represented as percentage of
control. As can be seen from figure 5.2, only 6 of the 94 strains tested had the ability to
degrade >20% of the quercetin that was supplemented to the media (indicated in orange).
This includes Bacillus glycinifermentans, Flavonifractor plautii, Bacteroides eggerthi,
Olsonella scatoligenes, Eubacterium eligens, and Lactobacillus spp.
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Figure 5. 2: Quercetin degradation by the human gut bacterial library
Figure shows the degrading capability of each bacterial species as percentage
degradation when compared to control. The results indicate that 6 strains (in orange) of the
94 strains tested exhibited >20% quercetin degradation.
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5.3.2 HPLC analysis of Bacillus glycinifermentans and Flavonifractor plautii reveal
different metabolites produced following quercetin degradation
Among the 6 bacterial strains that could degrade quercetin (>20%), Bacillus
glycinifermentans (B. glycinifermentans) and Flavonifractor plautii (F. plautii) exhibited
maximum quercetin degradation under anaerobic incubation for 48 h (Fig. 5.2). Therefore,
it was decided to focus on these two strains for their ability to biotransform quercetin under
experimental conditions. It is important to note that while B. glycinifermentans is a newly
identified bacteria [249, 250] present in the human gut, its abundance in the human gut is
not fully characterized. On the other hand, F. plautii appears to be fairly distributed in
individuals as reported in literature [251]. It is also important to highlight that under the
culture conditions, the growth of B. glycinifermentans was profuse while that of F. plautii
was sparce (Fig 5.3). As demonstrated in Fig 5.3, peak growth occurred at 21h and
subsequently decreased after 36h for B. glycinifermentans. On the other hand, the growth
pattern of F. plautii was slower but sustained over the time-period examined. This indicated
that these two bacteria have different growth patterns in 7N minimal media. Despite the
poor growth that F. plautii exhibited, it was able to degrade quercetin much faster than B.
glycinifermentans. A time-course of the degradation pattern of quercetin by these two
bacterial strains is shown in Fig. 5.4. As can be seen, the degradation of quercetin was
almost complete at 48h for B. glycinifermentans, while this was achieved within 12 h by
F. plautii.
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Figure 5. 3: Growth pattern of B. glycinifermentans (A) and F. plautii (B) in 7N
minimal media
The bacterial strains were inoculated to an OD600 of 0.05 and allowed to grow for
48h under anaerobic conditions. Aliquots from the culture media was removed periodically
and OD600 was measured at regular intervals.
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Figure 5. 4: Quercetin degradation pattern of different bacterial species
(A) Kinetics of quercetin degradation by B. glyinifermentans (B) Kinetics of quercetin
degradation by F. plautii
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HPLC analysis of the spent media for B. glycinifermentans and F. plautii revealed
that each bacterial species produced different metabolites upon incubation with quercetin
for 24 h. 2,4,6-THBA and 3,4-DHBA was clearly detectable in the spent media isolated
from B. glycinifermentans culture. The levels of 2,4,6-THBA was comparatively lower
than that of 3,4-DHBA (Fig. 5.5A), while 4-HBA and DOPAC was not detected. In
contrast, the spent media from F. plautii revealed the presence of DOPAC, however, 2,4,6THBA, 3,4-DHBA and 4-HBA were undetected (Fig. 5.5B). Consistent with the results
obtained in Fig. 5.4, F. plautii completely degraded quercetin within 24 h of exposure while
B. glycinifermentans showed > 60% quercetin degradation (Fig. 5.5).
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Figure 5. 5: Detection of metabolites generated by B. glycinifermentans (A) and F.
plautii (B) following quercetin degradation
HPLC revealed that B. glycinifermentans generated 2,4,6-THBA and 3,4-DHBA
(A) while F. plautii generated DOPAC (B) upon exposure to Quercetin for 24h.
Concentration, estimated through standard curves using pure compounds, of each product
is expressed in μg/ml.
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5.3.3 Degradation kinetics and different end products suggest different mechanisms
of quercetin degradation by B. glycinifermentans and F. plautii
The differences in the metabolites produced between B. glycinifermentans and F.
plautii possibly suggested that that these bacteria utilize different pathways for quercetin
biotransformation. Therefore, an investigation was carried out to determine the presence
of quercetin degrading enzyme activity in the culture supernatant and bacterial cell lysates.
Bacteria were grown under identical conditions as described in Fig. 5.5, and the supernatant
and bacterial cell lysates were obtained. When assayed for the quercetin degradation, B.
glycinifermentans exhibited higher units of enzyme activity in the supernatant when
compared to cell lysate (Fig. 5.6A). One unit of enzyme activity is defined as the amount
of enzyme required to convert 1 µmol of quercetin in one min at 25°C [177]. Interestingly,
the supernatant of F. plautii did not exhibit any quercetin degrading activity; its cell lysate
however showed minimal enzyme activity (Fig. 5.6B). Taken together, this indicates that
B. glycinifermentans mediated degradation of quercetin occurs possibly through a secreted
enzyme while F. plautii requires the live culture for the biotransformation of quercetin that
most likely occurs intracellularly or at the cell surface.

123

Figure 5. 6: Quercetin degrading enzyme activity as determined in the culture
supernatant and cell lysates of B. glycinifermentans (A) and F. plautii (B)
As can be seen from the figure, higher enzyme activity was observed in the culture
supernatant of B. glycinifermentans when compared to the cell lysate (A). In contrast,
minimal enzyme activity was observed in the cell lysate of F. plautii, while there was no
quercetin degradation observed in its culture supernatant (B).

5.3.4 Clonogenic assays with DOPAC
Clonogenic assay was performed to demonstrate the effectiveness of DOPAC
against colony formation in SLC5A8-pLVX and HCT-116 cells. Figure 5.7A demonstrates
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that in SLC5A8-pLVX cells, DOPAC decreased the colony formation beginning at 7.3
µM. In HCT-116 cells (Fig. 5.7B), higher concentrations of DOPAC were required to
inhibit colony formation (≥ 15.62 μM). The anti-proliferative effect of DOPAC, observed
in this study is similar to the observations reported previously in literature [145].

Figure 5. 7: Effect of DOPAC on SLC5A8-PLVX and HCT-116 colony formation
Effect of DOPAC on colony formation in (A) SLC5A8-pLVX cells and (B) HCT116 cells. Quantification of the data is shown beside the crystal violet stained image of the
colonies. The graph is represented as mean ± standard deviation. The concentration of the
drugs used are indicated as micromolar (μM).
5.3.5 Clonogenic assay using HCT-116 cells with spent bacterial culture supernatant
The results obtained in Fig 5.7 on the effect of pure DOPAC on HCT-116 and
SLC5A8-pLVX cells prompted us to examine the growth inhibitory properties of the spent
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bacterial culture supernatant on both cell lines. Bacterial cells were inoculated at an OD600
of 0.05 in 25 mL of 7N minimal media, with and without quercetin (37.5 μg/ml for B.
glycinifermentans and 75 μg/ml for F. plautii) and grown anaerobically for 24 h. These
concentrations were selected to ensure that incubation with the corresponding bacteria for
24 h, will result in complete degradation of quercetin (based on previous data). The culture
supernatant was then harvested through centrifugation, and any remaining bacterial
cells/particles were removed through filtration (0.22μm filters). HPLC analysis showed
that supernatants from both bacterial cultures contained only the metabolites and did not
contain any quercetin (data not shown), suggesting that any anti-proliferative effect
observed would most likely be linked to the metabolites. One milliliter of the sterile culture
supernatant was used for colony formation assay as described in Fig. 5.7. Following
incubation for 14-21 days, with three changes in medium and treatments, the colonies were
stained using crystal violet and colonies were counted. As can be seen from Fig 5.8, the
culture supernatant of B. glycinifermentans containing quercetin showed marginal
inhibition (~ 3% inhibition compared to supernatant without quercetin) whereas significant
inhibition was observed in the cells incubated with the culture supernatant of F. plautii
grown in the presence of quercetin (~ 65% inhibition compared to supernatant without
quercetin).
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Figure 5. 8: Clonogenic assay using HCT-116 cells treated with spent bacterial culture
supernatant
Effect of spent supernatants from B. glycinifermentans and F. plautii cultures
grown in the absence (-Quercetin) and presence (+Quercetin) of quercetin on colony
formation in HCT-116 cells. Quantification of the data is shown beside the crystal violet
stained image of the colonies. The graph is represented as mean ± standard deviation. While
in some plates the distribution of the 500 cells seeded were homogeneous, others had
clusters of cells localized to certain regions of the plate, owing to their placement in the
incubator. All plates were however seeded with 500 cells/plate and allowed to form
colonies.

The observed marginal effect of the B. glycinifermentans supernatant on HCT-116
cells is likely to be due to the lower concentrations of 3,4-DHBA and 2,4,6-THBA as
observed through HPLC (data not shown). Estimation of the metabolites in the culture
supernatant showed that 1 ml of the B. glycinifermentans supernatant contained 68.93 μg
and 16.17 μg of 3,4-DHBA and 2,4,6-THBA respectively. This roughly translates to 40.66
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μM of 3,4-DHBA and 8.64 μM of 2,4,6-THBA in a volume of 10 ml used for colony
formation assay. On the other hand, 1 ml of the culture supernatant from F. plautii
contained 20.45 μg of DOPAC, which is equivalent to 11.05 μM of DOPAC in 10 ml of
culture supernatant, and this concentration appears to be sufficient to cause inhibition of
cell proliferation. However, when we tested for the anti-proliferative ability of the bacterial
culture supernatants of B. glycinifermentans and F. plautii in SLC5A8-pLVX cells,
inhibition of colony formation was observed irrespective of whether the supernatant was
obtained from the bacterial cultures grown in the presence or absence of quercetin (Fig
5.9). This suggests that SLC5A8-pLVX cells are inherently sensitive to the components
present in the bacterial culture supernatant. Further work is required to identify the nature
of this inhibition.
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Figure 5. 9: Clonogenic assay using SLC5A8-pLVX cells treated with spent bacterial
culture supernatant
Effect of spent supernatants from B. glycinifermentans and F. plautii cultures
grown in the absence (-Quercetin) and presence (+Quercetin) of quercetin on colony
formation in SLC5A8-pLVX cells. As can be seen, there was inhibition of cell growth
irrespective of whether the supernatant was obtained from the bacterial cultures grown in
the presence or absence of quercetin, suggesting that some component of the bacterial
culture supernatant was inhibiting cancer cell growth. Further work is required to identify
the nature of this inhibition.
5.4 Discussion
The flavonoid quercetin has been implicated for its health benefits against numerous
disorders including inflammation, hypertension, obesity, and atherosclerosis [252].
Importantly, reports also indicate a role for quercetin in the prevention of many types of
cancers [224, 237]. Quercetin is predicted to exert its anti-cancer effects through numerous
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mechanisms including (a) interacting with growth receptors, (b) modifying signal
transduction pathways including the MEK/Erk pathway and Nrf2/keap1 signaling, (c)
through its antioxidant properties, and (d) apoptosis regulation [224-226]. Increasing
evidence in literature suggests that the metabolites of quercetin may be responsible for its
observed health benefits. Three observations that support a role for quercetin metabolites
include: (1) pH dependent degradation of quercetin in the intestine (in the basic
environment), (2) the low absorption of quercetin in the intestine resulting in low
bioavailability, and (3) the biotransforming capability of the resident gut microflora. The
results presented in this chapter has demonstrated the ability of select human gut bacteria
to generate the metabolites 2,4,6-THBA, 3,4-DHBA and DOPAC. These results now tie in
well with those presented in chapter 3 where we demonstrated the ability of some of these
metabolites to inhibit cancer cell growth. It also gives credence to the metabolite hypothesis
proposed in chapter 6 which suggests that: (1) bacteria are capable of biotransforming
flavonoids and (2) the cancer preventive actions of flavonoids are likely mediated by its
metabolites acting on specific cellular targets.
Our attempts to screen the human gut bacterial library yielded 6 bacteria capable of
degrading quercetin. These include B. glycinifermentans, F. plautii, B. eggerthi, O.
scatoligenes, E. eligens, and Lactobacillus spp. Of these strains, this is the first
demonstration of quercetin degradation by B. glycinifermentans, B. eggerthi, O.
scatoligenes, and E. eligens. All 6 species identified in this study have been demonstrated
to be present in human fecal content, suggesting that several species in the gut are capable
of biotransforming quercetin. Our demonstration of the ability of F. plautii and
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Lactobacillus species degrading quercetin is also consistent with previously published
reports [136, 243, 251, 253].
Although F. plautii has previously been reported to degrade quercetin to generate
DOPAC, studies described in this chapter, for the first time, has identified the ability of B.
glycinifermentans to biotransform quercetin to generate 2,4,6-THBA and 3,4-DHBA. This
is a novel finding. B. glycinifermentans, which was reported to be part of the human fecal
content by Ghimre et al. [175], was initially characterized as being present in fermented
soybean paste and hence the name B. glycinifermentans [249]. Interestingly, based on the
analysis of its complete genome, this bacterium was suggested for use as a probiotic for
livestock to enhance immune stimulation, enzyme production and pathogen inhibition
[250]. The link between our observation that it is capable of biotransforming quercetin to
generate 2,4,6-THBA and 3,4-DHBA, and its suggested use as a probiotic in the previous
report [250], makes this bacterial strain an interesting candidate for the maintenance of
human gut health. The isolates investigated in this study involved three Bacillus spp,
namely B. circulans, B. glycinifermentans and B. andreraoultii (Fig. 5.2). It is intriguing
to note that among these 3 strains, only B. glycinifermentans was able to biotransform
quercetin under experimental conditions, while the other 2 strains did not have any effect.
Further studies such as the comparison of the genome sequences or transcriptomic analyses
are needed to understand the unique ability of B. glycinifermentans to biotransform
quercetin when compared to the other two Bacillus strains.
The detection of DOPAC as a metabolite of quercetin generated by F. plautii in this
study confirms the previous reports in literature [251]. In this study, we did not detect the
presence of 2,4,6-THBA and 3,4-DHBA in the spent media from F. plautii. Although the
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reason for this is not currently known, it is clearly not related to the sensitivity of the
techniques employed, as both HBAs were detected in the spent media from B.
glycinifermentans. An interesting possibility is that the quercetin degradation pathway
utilized by F. plautii is radically different from that of B. glycinifermentans, and hence
generates different metabolites. This is supported by the observation that the spent culture
supernatant from B. glycinifermentans had quercetin degrading enzyme activity while this
was absent in the culture supernatant of F. plautii (Fig. 5.6). This observation also suggests
that the quercetin degrading enzyme in B. glycinifermentans and F. plautii is likely to be
differentially localized (secreted Vs membrane bound/intracellular). Also, from the
degradation kinetics, it is evident that F. plautii completely degrades quercetin within 12 h
of incubation, whereas B. glycinifermentans requires around 48 h for complete quercetin
degradation. This along with the minimal enzyme activity detected in the cell lysate (Fig.
5.6B) suggests that the degradation of quercetin by F. plautii may require the presence of
live bacterial cells. A recent study by Yang et al., demonstrated the involvement of enereductase, chalcone isomerase, enoate reductase and phloretin hydrolase in the generation
of metabolites from flavones and flavonols [245]. Hence, the lack of quercetin degradation
in the culture supernatant and minimal activity in the pellet observed in our study (Fig
5.6B) may also be related to the requirement of four different enzymes for the generation
of DOPAC from quercetin. Alternatively, it is also possible that the enzymes involved in
F. plautii is sensitive to the experimental conditions when assayed in vitro, which may not
be the case for B. glycinifermentans. Hence, further investigation should shed light on the
specific pathways utilized by these bacteria for quercetin degradation.
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The importance of 2,4,6-THBA and 3,4-DHBA in the inhibition of cancer cell growth
has been well established in the preceding chapters (Chapter 3), and in this chapter we have
demonstrated the anti-proliferative effect of DOPAC on cancer cells. It is to be noted that
DOPAC has also been shown to inhibit cancer cell proliferation by other investigators in
various cancer cell types [145, 243, 254]; this is believed to occur through its antioxidant
properties. The ability of B. glycinifermentans to degrade quercetin to 2,4,6-THBA and
3,4-DHBA, and F. plautii to generate DOPAC from quercetin suggests that, in an in vivo
scenario, the colorectal tissues are likely to be directly exposed to these anti-cancerous
metabolites. Interestingly, one report also demonstrated that F. plautii along with 3 other
bacterial species, was capable of inhibiting the growth of Clostridium perfringens, a
pathogenic bacterium, highlighting its importance in gut health [255].
Human gut is known to harbor 300-500 species of bacteria [256, 257], this study has
investigated the potential of only 94 bacterial strains to degrade quercetin. Therefore,
additional screening is required to establish the contribution of other bacterial strains to
CRC prevention as well. However, it is interesting to note that of the 94 strains screened,
only 6 of them exhibited the ability to degrade quercetin. This suggests that the flavonoid
biotransforming ability may be narrowly restricted to only a few species of bacteria,
highlighting the importance of these bacteria in the prevention of CRC. While the focus of
our study was on quercetin, it is to be noted that the diet also contains other flavonoid
members (such as anthocyanins, EGCG, Catechins, cyanidin-3-glucoside etc.) that may be
biotransformed by the gut microflora [258]. For example, DOPAC, 2,4,6-THBA and 3,4DHBA has been reported to be

metabolites produced upon green and black tea

consumption [145, 259] while 2,4,6-THBA and 3,4-DHBA have been demonstrated to be
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generated upon cyanidin-3-glucoside consumption [141]. Also, in this study, the bacterial
strains were grown individually to screen for their ability to degrade quercetin, it is still
unknown how quercetin may be degraded in the presence of other bacteria in co-cultures.
It is known that some bacterial species influence the growth of others, diet is also suggested
to contribute to this selection [258, 260]. Therefore, additional studies are required to
establish how diet influences the growth of these species and overall degradation of
quercetin in vivo. It will be interesting to explore the metabolism of quercetin by other
species of bacteria, enzymes involved in this process and characterize the metabolites
generated individually or in a community setting. Additional studies are also required, to
test the bacterial culture supernatants containing these metabolites, for their ability to
inhibit cancer cell proliferation. It is also important to emphasize that besides bacteria, the
microflora in the human gut also comprise of viruses, fungi and archaea [261] and hence
their contributions to cancer prevention may also be significant.
The studies described in this chapter has identified 6 strains of bacteria capable of
degrading quercetin to give different bio-active metabolites, some of which have been
previously characterized to have anti-proliferative effects against cancer cells. This study
also established clear differences between two bacterial species in terms of their ability to
degrade quercetin, in addition, also showed the generation of structurally different
metabolites. We believe that bacteria mediated biotransformation of flavonoids and
generation of the metabolites are important contributors to cancer prevention observed in
a diet rich in flavonoids.
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CHAPTER 6: SUMMARY, PERSPECTIVES, AND FUTURE STUDIES
Cancer is a genetic disease which arises due to mutations in protooncogenes and tumor
suppressor genes whose imbalances in expression leads to uncontrolled cell proliferation.
Therefore, effective preventive measures for cancer requires identification of compounds
that target proteins that regulate cell proliferation. In this regard, flavonoids and aspirin
hold great promise for the prevention of cancer; however, despite considerable efforts in
identifying their mechanism of action, a consensus has not been reached. It appears that
flavonoids and aspirin and their metabolites affect many enzymes, proteins, transcription
factors, and signaling pathways involved in cell proliferation and cancer development,
making the identification of its primary target difficult. An effort has been made in this
investigation to identify a common pathway that may explain the cancer prevention
properties of flavonoids and aspirin.
The studies carried out in this dissertation explored the role of metabolites in CRC
prevention by flavonoids and aspirin. The metabolites tested included 2,4,6-THBA, 3,4DHBA, 3,4,5-THBA, and 4-HBA known to be generated from flavonoid metabolism and
2,3-DHBA and 2,5-DHBA, known to be generated from aspirin metabolism. Studies were
conducted on how these metabolites affect CDK enzyme activity using commercially
obtained enzymes and the effect of these compounds on cancer cell growth were also
investigated. Additionally, a human gut bacterial library was screened for identifying the
bacterial strains capable of degrading the flavonoid quercetin, and the metabolites
generated were identified. The major findings from this study are indicated below:
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6.1 Summary from Chapter 3
•

2,4,6-THBA dose dependently inhibited CDKs 1, 2 and 4 enzyme activity,
however, 3,4-DHBA, 3,4,5-THBA and 4-HBA were ineffective in inhibiting these
enzymes. This suggests that the position and number of the hydroxyl groups in the
benzene ring may be key determinants for exerting inhibitory effects.
Phloroglucinol, that lacks the carboxyl group, failed to inhibit CDK enzyme activity
which demonstrated the importance of the carboxyl group in enzyme inhibition.

•

Molecular docking studies revealed key interactions of 2,4,6-THBA with CDKs 1,
2 and 4. The interactions were found to be in the active site of the enzymes,
suggesting that 2,4,6-THBA may compete with the ATP-binding site. This suggests
that these metabolites may act as ATP-competitive inhibitors.

•

Despite the potent inhibitory effect of 2,4,6-THBA on CDK enzyme activity, it
failed to inhibit cancer cell growth in HCT-116 and HT-29 colon cancer cells.
Further studies demonstrated that 2,4,6-THBA dose-dependently inhibited cancer
cell growth in a breast-cancer cell line expressing a functional MCT – SLC5A8
(SLC5A-pLVX cells). This demonstrated that a transporter function is necessary
for the growth inhibitory effect of 2,4,6-THBA.

•

Consistent with the growth inhibition observed in transporter expressing cells,
HPLC studies demonstrated significant and dose-dependent uptake of 2,4,6-THBA
in cells having functional transporters (SLC5A8).

•

In SLC5A8-pLVX cells, 2,4,6-THBA dose-dependently induced p21Cip1 and
p27Kip1 CDK inhibitory proteins as measured by qPCR and western blotting.
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•

Cell cycle analysis revealed that 2,4,6-THBA does not cause accumulation of cells
at any stage of the cell cycle; neither did it induce apoptosis. This suggests that
2,4,6-THBA possibly arrests cell cycle at all stages, without causing accumulation
at any particular stage, and without inducing apoptosis. These results also suggest
that 2,4,6-THBA is mostly a cytostatic agent than a cytotoxic agent.

•

As expected, 2,4,6-THBA failed to inhibit colony formation in HT-29, HCT-116
cells; however, it dose-dependently inhibited colony formation in SLC5A8-pLVX
cells. In contrast, 3,4-DHBA and 3,4,5-THBA inhibited colony formation in all
three cell lines, while 4-HBA did not inhibit colony formation in any cell line.
HPLC analysis further revealed that 3,4-DHBA and 3,4,5-THBA were not taken up
into the cells, and 4-HBA was taken up by all cell lines tested.

•

The results above show that 2,4,6-THBA causes cancer cell growth arrest through
a CDK and SLC5A8 -dependent pathway whereas 3,4-DHBA and 3,4,5-THBA
arrest cancer cell growth through a CDK and SLC5A8 -independent pathway. The
inability of 3,4-DHBA and 3,4,5-THBA to inhibit CDK, their lack of cellular
uptake and their ability to inhibit cell growth suggests that their targets are most
likely extracellular. These results suggest that although structurally related, the
targets and modes of actions for these HBAs are different in contributing to their
ability to prevent cancer cell growth.

6.2 Summary from Chapter 4
•

Aspirin metabolites 2,3-DHBA and 2,5-DHBA inhibited commercially available
CDK 1 and 6 enzyme activity in vitro.
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•

Consistent with the enzyme inhibition, these compounds also inhibited cancer cell
colony growth. However, it is to be noted that 2,5-DHBA was universally effective
and inhibited HT-29, HCT-116 and MDA-MB-231 cell lines while 2,3-DHBA was
more effective in MDA-MB-231 cells.

•

Molecular docking studies revealed key interactions of 2,3-DHBA and 2,5-DHBA
with specific amino acids in the active site of the CDK enzymes.

•

Structurally related derivatives of salicylic acid, 2,4-DHBA and 2,6-DHBA, which
were previously reported to inhibit CDK enzyme activity [166], failed to inhibit
colony formation in cancer cell lines tested.

•

Importantly, aspirin and salicylic acid themselves were not effective in inhibiting
both CDK enzyme activity and cancer cell colony formation even at 1 mM
concentration. This again highlights the importance of metabolites in aspirin’s anticancer effects.

6.3 Summary from Chapter 5
•

Ninety-four human gut bacteria were screened for their ability to degrade quercetin
under anaerobic conditions mimicking the human gut environment.

•

Six bacterial species – B. glycinifermentans, F. plautii, B. eggerthi, O. scatilogenes,
E. eligens, and Lactobacillus spp. exhibited the ability to degrade >25% of the
supplemented quercetin.

•

B. glycinifermentans degraded quercetin to yield 2,4,6-THBA and 3,4-DHBA.

•

F. plautii degraded quercetin to yield DOPAC.
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•

Besides the different metabolites, the kinetics of quercetin degradation by B.
glycinifermentans and F. plautii appear very different, suggesting that different
pathways may be utilized by these species for quercetin biotranformation.

•

This study also suggests the possibility that B. glycinifermentans and F. plautii may
be good probiotic candidates along with flavonoids to improve human gut health.
However, in vivo studies are required to explore this possibility.

6.4 The metabolite hypothesis – a common mechanism for cancer prevention
The results obtained in this dissertation has led to the proposal of a novel hypothesis
that potentially explains HBA as common mediators of cancer prevention by flavonoids
and aspirin. The unstable nature of flavonoids, the rapid hydrolysis of aspirin in the gut and
the reports on the cancer-preventive potential of their degraded products through inhibition
of cancer cell growth collectively suggest that the HBAs generated from flavonoids and
aspirin may be key contributors to their cancer prevention properties. Unabsorbed
flavonoids and aspirin/salicylic acid may act as substrates for the gut microbes to degrade
them into simpler HBAs generating 2,3-DHBA, 2,5-DHBA, 3,4-DHBA, 3,4,5-THBA and
2,4,6-THBA. This generation of HBAs in the gut compel us to propose a central role for
these molecules in cancer prevention by aspirin, flavonoids and the diet. As these HBAs
are metabolites generated through biotransformation in the body and are also secondary
metabolites in plants with the capacity to inhibit cancer cell growth, we would like to refer
to this hypothesis as “metabolite hypothesis”. A model depicting the convergence of the
pathways generating HBAs from aspirin, flavonoids and diet through microbial/host
enzymes is shown in Fig. 6.1. Cancer prevention by HBAs is relatively underexplored, and
further investigations are required to identify potential targets (intracellular vs.
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extracellular), their uptake mechanisms by cells, signaling pathways and target gene
expression. Such studies would have tremendous implications in developing new strategies
for cancer prevention. Table 6.1 describes the various metabolites generated from aspirin
and flavonoids and their varying abilities to inhibit CDKs and cancer cell growth.
Table 6. 1: Table showing the source of the HBA metabolites, their potential to inhibit
CDKs and their ability to retard cancer cell growth
Compound

Aspirin
metabolite

Flavonoid
metabolite

CDK
inhibition

Reference

+

Inhibition
of cancer
cell growth
+

2,3-DHBA

+

-

2,5-DHBA

+

-

+

+

[262]

2,4,6-THBA

-

+

+

+ (in the
presence of
a functional
SLC5A8)

[171]

3,4,5-THBA

-

+

-

+

[165, 171]

3,4-DHBA

-

+

-

+

[162, 171]

2,4-DHBA

-

+

+

-

[262]

2,6-DHBA

-

+

+

-

[262]

4-HBA

-

+

-

-

[171]

[262]
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Figure 6. 1: Metabolite hypothesis: Model depicting convergence of the pathways
generating HBAs from parent compounds through host/microbial enzymes
We propose that actions of HBAs, generated through biotransformation of aspirin
and flavonoids, retard rate of cell proliferation. This would provide an opportunity for
immune surveillance leading to either the destruction of cancer cells or DNA repair in cells
containing damaged DNA, providing genetic stability, both of which are important steps
in the prevention of tumorigenesis. While 2,4,6-THBA is likely to retard cell proliferation
through CDK inhibition and upregulation of p21Cip1 and p27Kip1, the exact mechanisms of
cell growth inhibition by other HBAs is still not understood [171, 262].
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6.5 Perspective on the role of flavonoid degrading bacteria and their metabolites in
decreasing CRC
Flavonoids being unstable, undergo degradation to generate simpler phenolic acids and
this process can occur through alterations in the pH, temperature and through microbial
degradation to generate phenolic acids making it likely that the colonic epithelial cells are
exposed to large amounts of these compounds. One of the major issues described in
connection with flavonoids is their poor bioavailability; yet, they have been described as
effective in reducing CRC. This raises the possibility that, along with the parent flavonoids,
the phenolic acids may significantly contribute to cancer prevention. Evidence published
from literature in the last 10 years are in favor of a role for the metabolites of flavonoids
rather than the parent compounds in cancer prevention. The studies described in this
dissertation further reiterates the importance of these metabolites in cancer prevention
observed for flavonoid compounds.
Of the four major metabolites generated from flavonoid metabolism, the observation
that 2,4,6-THBA inhibits CDK enzyme activity and cancer cell proliferation is highly
significant. These findings have not been reported previously, although some studies have
documented the ability of 3,4-DHBA and 3,4,5-THBA in inhibiting cancer cell growth in
vitro and tumor formation in vivo. As the A-ring of flavonoids is highly conserved, it is
expected that 2,4,6-THBA is likely to be a major phenolic acid metabolite, whereas the
generation of 3,4,5-THBA and 3,4-DHBA will depend on the hydroxylation pattern of the
B-ring. A novel finding of this dissertation is the ability of 2,4,6-THBA to inhibit CDKs 1,
2 and 4 enzyme activity and cancer cell growth. This observation has immense clinical
implications because 2,4,6-THBA has the potential to be used as a prophylactic compound
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for chemoprevention. Alternatively, derivatives of 2,4,6-THBA can also be developed as
novel inhibitors of CDKs, through modifications of their functional groups, which would
be useful for cancer treatment. Therefore, efforts should be focused in future investigations
on identifying the other potential targets for 2,4,6-THBA and their mechanism(s) of action
in colorectal tissues. An understanding of how flavonoids are degraded by the human
colonic bacteria may be useful to devise viable strategies to prevent the occurrences of
cancer through the use of appropriate probiotics and flavonoids. In this dissertation we
have identified 6 bacterial strains capable of degrading quercetin, suggesting their potential
use as probiotic supplements.
Increasing evidence in literature suggest a role for microbiota in human health. Human
gut has been shown to contain 300-500 species of microbes including bacteria, fungi, and
protozoa [256]. It is considered a separate organ by itself because the lack of such a
microbial community has serious effect on human physiology, biochemistry, and health.
Several studies have examined the effects of polyphenols against human gut microflora
including their influence on the composition and activity of beneficial and pathogenic
bacterial species. Polyphenolic compounds are abundant in green and black tea, in colored
fruits and vegetables, and in chocolate and red wine [77, 88]. The bioactive components in
the diet such as epigallocatechin gallate (EGCG), epicatechin gallate (ECG),
epigallocatechin (EGC) and catechins inhibit the growth of pathogens including
Helicobacter pyrolii, Staphylococcus aureus, E. coli O157:H7, Salmonella typhimurium
DT104, Listeria monocytogens, Pesudomonas aeruginosa, Hepatitis C virus, and fungi of
the Candida genus [263]. On the other hand, polyphenolic compounds have also been
shown to enhance the growth of commensals and beneficial bacteria, while suppressing the
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pathogenic strains [264]. Tea derived phenolic compounds and their derivatives have been
shown to inhibit pathogens such as Clostridium perfringens, and Clostridium difficile.
Interestingly, commensal anaerobic species such as Clostridium spp., Bifidobacterium
spp., and probiotics such as Lactobacillus spp. were less severely affected [265]. Other
studies also confirmed these findings and demonstrated that polyphenolic compounds alter
the gut microbial ecology by increasing the bacteria that are beneficial and therefore exert
a positive effect on gut health [266]. In view of reports suggesting that habitual
consumption of a diet rich in flavonoids affect the microbial ecology, along with the fact
that microbial dysbiosis in the gut can lead to the occurrence of CRC, the role played by
flavonoids in CRC prevention should be considered for further studies.
6.6 Perspective on aspirin metabolites in decreasing CRC
Aspirin’s preferential effects against CRC as compared to cancers of other tissues raises
the possibility that it may act directly on colorectal tissues before its absorption into
circulation. Such an effect requires substantial concentrations of aspirin in the intestinal
milieu which we believe is achievable. Since the bioavailability of aspirin is ~50% [101]
and there is significant hydrolysis of aspirin occurring in the intestine [102], colorectal
tissues are likely to be exposed to millimolar concentrations of aspirin and salicylic acid.
This is particularly true following consumption of enteric-coated tablets as its absorption
is significantly lower than regular aspirin [203, 267] making it more available in the lumen
of the intestine. In such an environment, both aspirin and salicylic acid can target specific
proteins in the colonic cells to modulate their function and bring about changes required
for effective chemoprevention. In this context, intact aspirin has the potential to target
proteins through acetylation, and along with salicylic acid, may also target specific

144

transcription factors such as NF-κB or c-myc in colorectal tissues. Alternatively, other
signaling pathways like Wnt/β-catenin or Akt/mTOR pathways may also be regulated as
described above by aspirin and salicylic acid under these conditions.
Equally important are also the role of aspirin metabolites 2,3-DHBA and 2,5-DHBA in
its chemopreventive effects. Both DHBAs have been demonstrated to inhibit CDK enzyme
activity and colony formation in cancer cells, although 2,5-DHBA was more potent when
compared to 2,3-DHBA [166, 268]. In view of the ability of intestinal bacteria, capable of
degrading aspirin and salicylic acid to DHBAs, their contribution to the chemopreventive
effect of aspirin should also be considered. Except for a few reports, a role for HBAs in
cancer prevention has not been investigated in depth [166, 212, 268]. Exploring the role
played by HBAs in aspirin’s cancer prevention should take precedence in future
investigations as they are also generated following degradation of flavonoids [141, 269271], which are known to prevent cancer. In addition, there is plenty of evidence in
literature that increased consumption of fruits and vegetables, that is rich in HBAs, is
inversely correlated to the occurrences of cancer [272, 273]; an interesting target proposed
for HBAs are CDKs present in colonic epithelial cells [166, 171, 274]. If one considers
HBAs as possible common mediators of CRC prevention, it provides the simplest
explanation through which all three compounds (aspirin, flavonoids and a diet rich in
HBAs) can exert anti-cancer effects. Thus, the metabolite hypothesis borne out of the
finding that HBAs inhibit cancer cell growth needs to be explored in future research with
regards to its targets and mechanisms of action.
Interestingly, in one randomized clinical study, aspirin was shown to increase the
abundance of Prevotella, Akkermansia, and Ruminococcaceae species while decreasing

145

the levels of Bacteroides, Parabacteroides and Dorea species, that have collectively been
associated with reduced CRC risk [275]. Another in vivo experiment with germ-free and
conventionalized mice also demonstrated that aspirin was able to increase the probiotic
bacteria Bifidobacterium and Lactobacillus, suggestive of a role in CRC prevention.
However, this study also demonstrated that the aerobic microbe Lysinibacillus sphaericus
was capable of degrading aspirin in the lumen; supplementation with antibiotics prevented
such microbe-mediated aspirin degradation. Their study also pointed out the ability of
aspirin to inhibit tumor formation in germ-free mice, raising the possibility that aspirin may
prevent CRC through a microbiome-independent mechanism, and suggested that this may
involve inhibition of COX-2 and PGE2 synthesis [276]. This raises the possibility that
aspirin may exert anti-cancer effects independent of the formation of metabolites. A role
for aspirin in increasing the beneficial bacteria which may contribute to human gut health
and cancer prevention requires additional study. Under normal conditions, a portion of
aspirin taken orally may be left unabsorbed, and therefore has the potential to act directly
on colorectal tissues. However, aspirin may also be subjected to metabolism, generating
2,3-DHBA and 2,5-DHBA, that in turn act on the colorectal tissues to prevent cancer. As
2,5-DHBA and 2,3-DHBA have been shown to inhibit cancer cell growth [212, 268], it
would be interesting to determine if these aspirin metabolites can potentiate the cancer
preventive properties of aspirin when administered to germ-free mice. Such studies should
validate the significance of both intact aspirin and its metabolites collectively contributing
to CRC prevention.
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6.7 Conclusions
It has been established over the course of time that increased consumption of fruits and
vegetables has health benefits, making Hippocrates’ dictum “Let food be your medicine
and medicine your food” all the more significant. Identification of polyphenols and
phenolic acids commonly found as a component of the diet has now led to the generation
of nutraceutical and/or pharmaceutical compounds that have revolutionized the health
sector. Considering the increasing incidences of CRC worldwide, it is now more important
than ever to come up with viable preventive strategies against this deadly disease. We
believe that HBAs merit further studies to understand their role in cancer prevention as the
proposed mechanism (metabolite hypothesis) involving HBAs is a simple and tenable
explanation for CRC prevention by both aspirin and flavonoids. Since intestinal epithelial
cells are the first to get exposed to HBAs following their consumption or metabolism (from
aspirin/flavonoids), in our view CRC prevention is likely to be a local effect. The colorectal
tissues may thus have an anatomical advantage as they are the first to get exposed to these
HBAs, making them preferred targets. We believe that effective cancer prevention requires
the partnership between the parent compounds and the right microbial species responsible
for HBA generation. We also propose that the variability previously observed in many
epidemiological studies [64, 83, 277] could be attributed to the lack of an appropriate
microbial ecology necessary for their degradation. Therefore, a strategy involving
supplementation of the diet with appropriate probiotics and aspirin/flavonoids, or directly
consuming HBAs may prove useful in CRC prevention. In this regard, the bacterial strains
identified in this dissertation (B. glycinifermentans, F. plautii, B. eggerthi, O. scatoligenes,
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E. eligens, and Lactobacillus spp.), merit further investigation for their use as probiotics to
improve gut health.
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